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Topical hemostatic agents have been used for thousands of years to stop bleeding. The an-
cient Egyptians applied fresh meat to a wound on the first day as a hemostatic agent. In the 
following days, treatment was continued with grease, herbs and honey [1]. In ancient Greece, 
wounds inflicted on the battlefield, were treated with herbs that were also described to have 
analgesic effects. Unfortunately, the used plants were not documented and still remain un-
known [2]. Native Americans are thought to have used scrapings from the inside of fresh 
animal hides mixed with hot sand and downy eagle feathers as topical hemostatic agent [3].
Nowadays, many topical hemostatic agents are available to the surgeons, dentists and ER 
personnel. These agents include gauze sponges, absorbable gelatin sponges, absorbable col-
lagen sponges, oxidized cellulose, chitin dressing, platelet concentrates and fibrin sealants. 
Gelatin, collagen and cellulose hemostatic agents are among the most widely used absorb-
able agents since several decades and will be described in more detail [4]. More recently, 
gelatin and collagen are increasingly combined with topical thrombin as this is the final en-
zyme of the clotting cascade [5]. 
Gelatin
Gelatin, a porous form of denatured collagen, was introduced as a topical hemostatic agent 
in 1945 [6]. Gelatin foam is manufactured from animal skin gelatin whipped and baked into 
its sponge form [4]. It provides a physical matrix in which a clot can form while absorbing 
surrounding fluids [7]. The large surface area of the numerous interstices may attract and 
damage platelets in the blood which enters the sponge, thus, liberating thromboplastin [8]. 
The material can be applied as a film, sponge or powder. According to the literature, it is im-
portant to note that gelatin sponges swell more than collagen products and can cause com-
pressive complications, especially when used near nerves or in confined spaces [9]. Although 
gelatin is derived from animal products, it is largely nonantigenic. Absorption of the gelatin 
foam is completed within 4 to 6 weeks [4].
Collagen
Microfibrillar type I collagen was developed as a topical hemostatic agent by Hait in 1970. It 
is derived from bovine corium and is available in powder form, a nonwoven sheet and as a 
sponge [9]. When the collagen gets into contact with blood, platelets adhere to the collagen 
fibrils and become activated [10]. The activated platelets change their shape from discoid 
to spherical and release procoagulant factors like adenosine diphosphate (ADP) and throm-
boxane A2 [11]. This activation leads to platelet aggregation and thrombus formation [12]. 
Hemostasis is usually achieved within 2 to 5 minutes. Since its mechanism of action depends 
on platelet activation, it is less effective in patients with severe thrombocytopenia, but suc-
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cessfully achieves hemostasis even after large doses of heparin [13]. Some swelling occurs, 
although this is less than the swelling of gelatin [4]. Collagen is only mildly immunoreactive 
and degradation of the material is completed in 6 to 12 weeks [14].
Cellulose
Oxidized cellulose was introduced in 1942, wheras oxidized regenerated cellulose was de-
veloped in 1960 and is manufactured from wood pulp, which contains about 50% cellulose 
by mass. In order to obtain purified cellulose, it has to be decomposed and than recomposed 
into regenerated cellulose [4]. Cellulose acts as a physical matrix for clot formation, although 
the exact mechanism of its action is unknown but probably depends on surface interactions 
with proteins and platelets [4,15]. The material also seems to confer hemostasis by decreas-
ing the pH and acting as a caustic agent leading to hemostasis by generating an artificial clot 
[16]. The cellulose hemostatic agent can absorb up to 7 times its own weight and its great-
est use has been for the control of oozing from broad surfaces [17,18]. Although the low pH 
exerts an antimicrobial effect, it might also increase inflammation of surrounding tissue and 
delay wound healing [19]. Because of this risk of foreign body reactions, it is recommended 
that the smallest possible amount of cellulose be used and that it be removed once hemo-
stasis is achieved [9]. It may take up to 6 weeks to fully degrade, but its presence has been 
detected as late as 1 year when used in cardiac surgery [9,20].
Possible antigenicity and pathogen transmission of collagen and thrombin
Injectable soluble collagen was approved by the US Food and Drug Administration (FDA) in 
1981, to be used as a subcutaneous implant to correct minor dermatological defects. Soon 
after its widespread use, questions about its antigenicity were raised [21,22]. This caused 
concern in the medical community over the use of collagen in general. Approximately 3% of 
patients developed a hypersensitivity reaction to the bovine collagen implant during a stan-
dard forearm skin test [23]. Another report indicated that an additional 5% of the patients 
whose screening test were initially negative will have serum antibodies to collagen [24]. In 
1991 another problem arose in Europe when it was found that cattle were dying from a syn-
drome known as bovine spongiform encephalitis (BSE). The infectious agent that causes BSE 
disease was found to be a prion (a proteinatious particle) that also causes scrapie in sheep 
and goats. As this infectious agent apparently crossed the species barrier, concern was raised 
over the use of bovine products, especially those used in medical products [14]. Although 
there is no report of human BSE-infection from collagen-based medical devices, the raw ma-
terial of the collagen should not come from a country with known BSE cases [19]. 
The antigenicity of topical bovine thrombin has also raised concerns because of the poten-
tial for antibodies directed against the product [5]. The development of antibodies directed 
against bovine coagulation factors like thrombin and clotting factor V has been reported in 
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patients treated with various bovine thrombin preparations [25]. The resulting antibodies can 
cross-react with human endogenous coagulation proteins and might lead to coagulopathies 
like severe bleeding or thrombosis [26-31]. Because of these safety concerns, recombinant 
human thrombin was developed to provide an alternative to bovine thrombin. Recombinant 
human thrombin has been shown to be considerably less immunogenic than bovine throm-
bin while the efficacy is similar [5].
Although the clinical impact of antigenicity and potential pathogen transmission is low up 
till now, a fully synthetic biodegradable hemostatic agent would prevent the potential risk of 
blood-borne pathogen transmission and immunization. Furthermore, the production process 
of a synthetic material allows greater control over material properties and tissue responses, 
which gives a synthetic material another advantage over animal-derived products [32]. The 
animal-derived hemostatic agents are relatively cheap materials. Therefore, a new synthetic 
topical hemostatic agent should preferably be made of a material that can be produced at 
the same low cost.
Polyurethane
A synthetic material that has been investigated extensively is biodegradable polyurethane 
(PU). Its possible hemostatic properties were recognized by Van Minnen who studied the 
biological behaviour of PU and its applications in dentoalveolar surgery [33]. Polyurethane 
is a polymer in which the repeating unit contains a urethane moiety. Urethane linkages are 
formed by the reaction of isocyanates (-N=C=O) with hydroxyl (-O-H)-functional molecules 
like polyol [34]. In this reaction the hydrogen atom of the hydroxyl group is transferred to 
the nitrogen atom of the isocyanate [35]. The general formula for polyurethane is shown in 
figure 1 [36].
Segmented polyurethanes have been used as biomaterials for several decades due to their 
biocompatibility and favorable physical properties like strength and flexibility [37].
These first polyurethanes were intended for use as long-term implant materials such as 
pacemaker lead insulators [38]. After years of production of PUs, manufacturers found them 
susceptible to degradation [36]. Therefore, a lot of research has been performed to elucidate 
the mechanisms of degradation and increase the biostability of PU [39-41]. In contrast, the 
development of intentionally degradable biomedical polyurethanes has received relatively 
O O
(–R–O–C–NH–R2–NH–C–O–) n
Figure 1. General formula of polyurethane.
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little interest [42]. The main reason for this lack of interest was due to the use of the toxic 
aromatic diisocyanate precursors (e.g. toluene diisocyanate) which may lead to carcinogenic 
compounds when the polyurethane is degraded [43]. The development of non-toxic aliphatic 
amino acid-derived diisocyanates has removed the obstacle to synthesizing degradable poly-
urethanes [44,45]. This has led to the development of biomedical PUs that are designed to 
biodegrade and remodel to form functional tissue [34]. The most common approach to the 
synthesis of these degradable polyurethanes has involved the use of polyester soft segments 
like polyhydroxyacids and poly-ε-caprolactone [46-48]. By varying the molecular structure, 
the rate of hydrolysis and therewith the degradability could be controlled [49]. The combina-
tion of hard and soft segments provides the polyurethane with its unique physical properties, 
such as flexibility in combination with mechanical strength [50].
The degradability of PU can be further increased by combining it with polyethylene oxide 
(PEO) [42,51]. This is attributed to the hydrophilic nature of PEO because the presence of a 
greater volume of water within the polyurethane can allow for a greater amount of hydrolysis, 
and thus degradation, to take place [52].
The polyurethane described in this thesis has uniform hard segments composed of butane-
diol and 1,4-butanediisocyanate and soft segments of DL-lactide and ε-caprolactone. The 
hard segments had a uniform length of five urethane moieties. The good biocompatibility of a 
comparable PU has been demonstrated in an in vivo study [53]. In this study the PU samples 
were resorbed almost completely after three years. A more rapid degradation period would 
be favorable to take away the risk of secondary inflammation. To increase the degradability, 
polyethylene glycol (PEG) which chemical properties are identical to PEO, was added to the 
material. The details of the composition and the synthesis of the polyurethanes investigated 
in this thesis are described in the Materials & Methods sections of Chapters 2 to 6.
Anticoagulant therapy
The use and need for topical hemostatic agents might increase with the aging population 
of Western society. As cardiac diseases and the subsequent risk of thrombo-embolism are 
more frequent among the elderly, an increasing number of patients might be considered for 
anticoagulant therapy [54]. These patients show a tendency towards higher bleeding risk and 
might benefit from hemostatic agents, during acute surgical procedures or after traumatic 
injuries [55].
With respect to anticoagulant therapy, special attention has to be paid to intraoral surgical 
procedures. At the Academic Centre for Dentistry Amsterdam (ACTA) in the Netherlands, a 
guideline has been developed that recommends continuation of anticoagulant therapy dur-
ing dentoalveolar surgery under well-described conditions [56]. The potentially higher bleed-
ing risk is accepted because discontinuation of anticoagulant therapy can result in throm-
boembolic events that may have far more severe consequences than limited postoperative 
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bleeding [57]. The guideline [56] was developed by gathering the best available evidence on 
this subject in the literature. The practical consequences in the Dutch setting have not been 
investigated. 
The antifibrinolytic agent tranexamic acid has an important role in this guideline. This agent 
works by competitively inhibiting the activation of plasminogen, reducing the formation of 
plasmin, which is responsible for the degradation of fibrin clots [58]. Although typically ad-
ministered intravenously, tranexamic acid has been used topically to control bleeding in a 
variety of specialities [59]. It significantly reduced mean blood losses after oral surgery in 
patients with haemophilia and was effective as a mouthwash in dental patients receiving oral 
anticoagulants [60-62].
Aims of this thesis
The aim of the present thesis was threefold:
1. To assess the hemostatic efficacy of polyurethane foam with polyethylene glycol 
and its working mechanism.
2. To analyse the time to complete degradation and biocompatibility of polyurethane 
foam with polyethylene glycol.
3. To evaluate the risk of bleeding incidents after dentoalveolar surgery in patients on 
oral anticoagulant therapy.
The hemostatic efficacy of PU was compared to commercially available hemostatic agents in 
vitro (chapter 2), in vivo (chapter 3) and in a rat tail-tip study (chapter 4). The hemostatic 
action and mechanical properties of PU were analysed and compared to gelatin and collagen 
in chapter 5. 
In chapter 6, the degradation process and biocompatibility of PU in rats and rabbits is de-
scribed and compared to gelatin and collagen. 
The bleeding incidence after dentoalveolar surgery in patients with and without anticoagu-
lant therapy was evaluated in chapter 7.
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Topical hemostatic agents can be used to treat problematic bleedings in patients who un-
dergo surgery. Widely used are the collagen- and gelatin-based hemostats. This study aimed 
to develop a fully synthetic, biodegradable hemostatic agent to avoid exposure to animal 
antigens. In this in vitro study the suitability of different newly developed polyurethane-based 
foams as a hemostatic agent has been evaluated and compared to commonly used agents.
An experimental in vitro test model was used in which human blood flowed through the test 
material. Different modified polyurethane foams were compared to collagen and gelatin.
The best coagulation was achieved with collagen. The results of the polyurethane foam im-
proved significantly by increasing the amount of polyethylene glycol. 
Therefore, the increase of the polyethylene glycol concentration seems a promising ap-
proach. Additional in vivo studies will have to be implemented to assess the application of 




Topical hemostatic agents can be used to treat problematic bleedings in patients who under-
go surgery. The benefits of local hemostats include improving blood conservation by reduc-
ing blood loss, shortening the time of hemostasis, avoiding the adverse effects of systemic 
hemostatic drugs and saving transfusion blood. Adverse effects can be foreign body reaction, 
infection, and granuloma formation [1]. Different types of hemostatic agents are available, 
each with their own characteristics. The following characteristics should be considered in 
search of an ideal hemostatic material: ease of application and removal, bioresorption po-
tential, suturability, antigenicity, and tissue reactivity effects [2]. The possibility to adjust ab-
sorbability and flexibility of the material would be a further advantage [3]. Some of the most 
widely used topical hemostatic agents nowadays are collagen and gelatin which are animal-
derived products. Procoagulant substances like thrombin or fibrin are frequently added to 
these agents to increase their hemostatic efficacy [1].
However, the use of products from animal or human origin has the potential risk of blood-
borne pathogens and immunization. Examples are Bovine Spongiform Encephalopathy (BSE) 
and Creutzfeldt-Jakob disease. Bovine collagen intended for collagen-based medical devices 
should therefore not come from a country with known BSE cases [1]. The use of bovine-
derived components in hemostats has resulted in a number of reports of immunization to 
bovine thrombin. The resulting antibodies can cross-react with blood clotting factor V and 
lead to coagulopathy [4]. 
A fully synthetic, biodegradable material with hemostatic properties would prevent these 
potential risks. Polyurethane (PU) with uniform hard segments composed of butanediol and 
1,4-butanediisocyanate and soft segments of DL-lactide, ε-caprolactone and polyethylene 
glycol (PEG) is a synthetic biodegradable material with possible hemostatic properties. Co-
agulation is initiated upon exposure to a PU surface while the PEG makes the material more 
hydrophilic which increases the attraction of platelets [5]. In a previous in vivo study the good 
biocompatibility of a comparable PU without PEG moieties has been demonstrated [6]. 
It is not known whether PU foam has hemostatic properties or can be modified to a hemo-
static agent. We questioned in this in vitro study if PU foam can achieve similar hemostatic 
properties as commercially available products. Therefore, PU foams were compared to an 
absorbable collagen hemostat (Novacol) and an absorbable gelatin sponge (Spongostan). Dif-
ferent modifications were applied to the PU foam to test whether they might increase its 
hemostatic efficacy. The PU foam was enriched with rFVIIa (recombinant factor VIIa), phos-
pholipids, ADP (adenosine diphosphate) and thrombin. Factor VII is one of the central pro-
teins in the coagulation cascade. When factor VIIa forms a complex with tissue factor (TF) the 
extrinsic pathway of the coagulation cascade is initiated [7]. Phospholipids greatly enhance 
the binding of factor VIIa to TF. ADP interacts with platelets, leading to further platelet activa-
tion [8]. Thrombin is a coagulation protein that has many effects in the coagulation cascade 
including platelet activation and the conversion of fibrinogen into fibrin [9]. Furthermore, 
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some of the PU foams were treated with ‘plasma glow discharge’ which creates a more hy-
drophilic foam with enhanced platelet binding and activation [10].
An experimental in vitro test model was used in which fresh human whole blood flowed 
through the test materials. This test model was based on the Thrombostat 4000® which is 
used to measure in vitro bleeding time and volume [11].
Materials
In this study tests have been performed with PU, Novacol (absorbable collagen hemostat; 
Bioprof BV, Moerkapelle, the Netherlands) and Spongostan (absorbable gelatin sponge; John-
son & Johnson, Skipton, UK).
The used PU is a block-copolymer composed of urethane hard segments and co-polyether-
ester soft segments. This was done to achieve a more rapid degradation. The soft segments 
(total molecular weight: 2.000 g/mol) consisted of 50% DL-lactide and 50% ε-caprolactone. 
In a first PU foam formulation, PEG 1.000 was used as initiator for the soft segments synthe-
sis. In a second PU formulation, PEG 20.000 was added after the synthesis in a mass ratio 
of 3 (first PU formulation) to 1 (PEG 20.000) to prepare a blend. The urethane segments 
were synthesized with 1,4-butanediisocyanate (BDI) and 1,4-butanediol (BDO). They had a 
uniform length of 5 urethane moieties, which resulted in a PU with BDI-BDO-BDI-BDO-BDI 
urethane segments in the polymer. The PU was then dissolved in 1,4-dioxane. After dissolv-
ing, the solution was poured into a mold and cooled down to −18°C. The solution was freeze-
dried at 3 mbar to remove the 1,4-dioxane crystals, resulting in an highly porous foam with a 
porosity of 97% and an overall PEG-content of 40 wt%. Overall porosity was calculated after 
determining the weight and dimensions of the foams.
The second PU foam formulation created a much more hydrophilic foam due to the increased 
PEG concentration. This foam had a porosity of 97% and an overall PEG-content of 55 wt%. 
The foams were processed to round slices with a diameter of 4 mm and a thickness of 2 mm. 
The foams were ultimately sterilized using ethylene oxide (EtO). The polymers and foams 
were manufactured by Polyganics BV (Groningen, the Netherlands). The collagen and gelatin 
materials were, like the PU foams, processed to round slices with a diameter of 4 mm and a 
thickness of 2 mm.
After the sterilisation process 145 foams were modified to potentially increase their hemo-
static efficacy. This was done by adding 10 µl of a procoagulant substance or surface treat-
ment. In table 1 an overview is presented of the added procoagulant substances and surface 
treatment. 
Procoagulant substances
Prior to adding the substances, the PU foams were treated for 15 minutes with 5 µl of a 15% 
glutaraldehyde solution to increase the attachment of the substances. Treatment with glu-
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taraldehyde is a procedure which can be employed to stabilize the binding of enzymes [12]. 
The excess of glutaraldehyde was washed away with copious amounts of phosphate buffer 
solution (pH 7.4) and ultimately with ultra-pure water. The substances were immediately ap-
plied to the foams one hour before testing using a volumetric pipette.
Surface treatment
Glow discharge treatment was performed at 50 W during 5 minutes at both sides. Vacuum 
was achieved by a dual trap vacuum pump and was always lower than 1800 Pa prior to ar-
gon (99.996%, Hoekloos Nederland B.V., the Netherlands) inlet. The argon pressure during 
plasma treatment was 500 Pa. After glow discharge, the reactor chamber was ventilated 
with ambient air. The surface characterisation of the treated PU foams was analysed by X-ray 
photoemission spectroscopy. This showed an increase of oxygen and nitrogen which resulted 
in a lower contact angle and thus higher hydrophilicity.
Methods
Blood preparation
The study was approved by the ethics committee of the University Medical Center Gronin-
gen, the Netherlands. The blood that was used for this study was obtained from 10 healthy 
adult volunteers. Exclusion criteria were a known disease or use of drugs that could have 
influence on blood coagulation. Each volunteer donated 30 ml of blood which was tested for 
normal trombocyte count. To prevent the blood from instant clotting, heparin was added to 
a concentration of 1.5 IU of heparin per ml blood. The blood was then divided over 30 mi-
crocentrifuge tubes, one ml per tube and kept at room temperature. This way 30 tests could 
be performed from each blood donation, the tests were finished within two hours after the 
blood was obtained. Each session the materials were tested in a different order to level the 
influence of time after the blood donation. A series of tests was performed without material 
Table 1. Overview of the added substances to the PU foams.
PEG concentration of PU 
foam (Wt%)




40 Recombinant FVIIa (0.1 mg/ml) 30
40 Phospholipid solution (100 mg/ml) 20
40 Adenosine diphosphate (ADP) (0.085 mg/ml) 20
40 Bovine thrombin (100 NIH U/ml) 10
55 Recombinant FVIIa (0.1 mg/ml) 25
40 Saline (0.9% NaCl) 10
40 Plasma glow discharge 30
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as a control group. Recombinant tissue factor (rTF) in a concentration of 5 pM was added to 
each ml of blood to resemble the wound situation in vivo. This was necessary because no de-
tectible concentrations of active TF are present in the blood of healthy donors [13]. While in 
a wound situation, extravascular TF is exposed to the blood and binds plasma factor VIIa [7]. 
Test device
An experimental in vitro test model was used which was based on the Thrombostat 4000® 
(Von der Goltz, Seeon, Germany). This device was used because of the possibility to insert 
different test materials in an existing model for measuring hemostasis in vitro. In this model 
blood flowed through the fixated test materials with a constant pressure of -40 mbar. Suction 
of the blood was performed through a needle with a diameter of 200 µm to create shear stress 
(Figure 1). The shear stress was necessary to mimic capillary bleeding which is an important 
platelet activator in vivo. The Thrombostat calculated the amount of blood flow through the 
test material over a period of 90 seconds. As a derivative for the extent of coagulation the 
blood flow deceleration was determined. This was calculated out of the blood volume that 
had passed the test material after 30, 60 and 90 seconds. The volume after 30 seconds was 
used to obtain the velocity of blood flow at 30 seconds. This was done by dividing the volume 
after 30 seconds by 30 and defined as initial velocity (Vi) in µl/s. The final velocity (Vf) in µl/s 
was calculated by dividing the volume that had flowed between 60 and 90 seconds by 30. 
The deceleration (d) in µl/s2 could be calculated by dividing the difference between initial and 
final velocity by the time interval in seconds (t) using the formula d = (Vf-Vi)/t.
Figure 1. In vitro test model. Suction of human whole blood was performed with a constant pressure of 





Needle, Ø 200 µm





The extent of thrombin generation in vitro was determined by measuring thrombin-anti-
thrombin complexes (TAT) in two of the blood samples. The measurement was performed 30 
minutes after venous blood collection. In two of the blood samples that had flowed through 
the PU foam (55 wt% PEG) with and without rFVIIa the amount of TAT was also determined. 
After the experiment 500 µl of blood was collected and added to 50 µl EDTA-solution (0.1 
mol/ml) to prevent further generation of thrombin. The blood sample was then centrifuged, 
and 200 µl of the supernatants were collected and stored at -20°C until further analysis. En-
zyme-linked immunosorbent assay (Cedarlane Ltd., Burlington, Ont., Canada) was employed 
for measurement of the TAT complexes.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0. Group differences were calculated by the 
Mann-Whitney-U-test. P values less than 0.05 were considered statistically significant.
Results
The mean decelerations and their standard deviations were calculated per material and are 
presented in order of efficacy in table 2.
For a clear overview the mean decelerations are also presented in a boxplot (Figure 2). 
Table 2. Mean deceleration and standard deviation of the different materials.
Material Mean deceleration (µl/s2) Standard deviation
Collagen 0.036 0.022
Gelatin 0.021 0.016
PU (55 wt% PEG) 0.015 0.007
PU (55 wt% PEG) + rFVIIa 0.015 0.006
PU + glow discharge 0.012 0.011
PU + thrombin 0.009 0.011
PU + saline 0.008 0.005
PU (40 wt% PEG) + rFVIIa 0.004 0.011
PU (40 wt% PEG) 0.002 0.010
No material -0.001 0.009
PU + ADP -0.002 0.015
PU + PL -0.003 0.015
PU, polyurethane; PEG, polyethylene glycol; rFVIIa, recombinant factor VIIa; ADP, adenosine diphosphate; PL, 
phospholipids.
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The best results were achieved with collagen which performed significantly better than the 
other materials (p<0.001). The second best results were achieved with gelatin which per-
formed significantly better than the control group without material and than the PU foams 
with 40 wt% PEG, with or without rFVIIa (p<0.001). The PU foams with 40 wt% PEG showed 
no significant difference compared to the control group without material. The PU foams with 
55 wt% PEG showed a significantly higher deceleration than the PU foams with 40 wt% PEG 
(p<0.02). Again the addition of rFVIIa to the foams gave no improvement of the results. No 
significant difference was observed between the PU foams with 55 wt% PEG and gelatin.
The results of the modified PU foams (40 wt% PEG) are also presented in a boxplot (Figure 3).
In the group with the modified PU foams, collagen again performed significantly better than 
the other materials (p<0.001). The PU foams which were treated with ‘plasma glow dis-
charge’ showed a significantly higher deceleration than the tests without material (p<0.02). 
The PU foams which were enriched with phospholipids, adenosine diphosphate, saline and 
thrombin showed no significantly different results from the tests without material. 
The blood took an average time of 12.1 seconds (SD: 0.83) to reach the material after suction 
was started. When the blood took more than 14 seconds to reach the material the results 
from these tests were excluded. This was the case in 23 out of the 308 tests.
Thrombin-antithrombin complexes (TAT)
Three duplo measurements were performed to assess the amount of TAT complexes before 
and after flow through the PU foam (55 wt% PEG) with and without rFVIIa. Results of this 
measurement are presented in table 3.
The plasma concentration of TAT complexes in vitro 30 minutes after venous blood collection 
is above the normal range (1.0 - 4.1µg/L) in vivo [14]. Approximately the same concentration 
of TAT was found in the blood samples that had flowed through the PU foam (55 wt% PEG) 
without rFVIIa. The blood samples that had flowed through the PU foam (55 wt% PEG) with 
rFVIIa showed a higher concentration of TAT complexes.
Table 3. Thrombin-antithrombin complexes in the different blood samples.
Blood sample TAT (mg/L) Standard Deviation
Before testing 1.38 0.06
After PU 1.36 0.07
After PU + rFVIIa 2.40 0.12
PU, polyurethane; rFVIIa, recombinant factor VIIa.
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Figure 2. Schematic representation of decel-
erations for the different test materials. The 
number of tested samples (n) is noted. PU, 
polyurethane; PEG, polyethylene glycol; rFVIIa, 
recombinant factor VIIa. For each group, the line 
in the middle of the box represents the median. 
The lower and the upper edges of the box are 
the 1st and 3rd quartile, respectively. The fences 
are drawn to the nearest value not exceeding 
1.5 (interquartile range). *P<0.001 compared 
with control group (No Material).
Figure 3. Schematic representation of decelera-
tions for the different modified PU foams (40 
wt% PEG). The number of tested samples (n) is 
noted. The results of collagen have been added 
to this boxplot as a reference. PU, polyurethane; 
PL, phospholipids; ADP, adenosine diphosphate; 
GD, glow discharge. For each group, the line in 
the middle of the box represents the median. 
The lower and the upper edges of the box are 
the 1st and 3rd quartile, respectively. The fences 
are drawn to the nearest value not exceeding 
1.5 (interquartile range). *P<0.001 compared 
with control group (No Material). **P<0.05 



































































































































An experimental in vitro test model was used to compare the synthetic PU foam to commer-
cially available hemostatic materials. Additional rTF was added to the blood to more closely 
resemble the wound situation in vivo. Different modifications have been applied to the PU 
foam to increase its hemostatic efficacy. The addition of rFVIIa to the PU foam did not influ-
ence the results. The effect of intravenous rFVIIa has been proven to reduce blood loss in 
severe blunt trauma patients in a multicenter randomized controlled trial [15]. In a study in 
rats the local use of a microporous polysaccharide hemosphere (MPH) in combination with 
freeze-dried rFVIIa significantly improved hemostasis [16]. The failure of rFVIIa to improve 
the results of PU foam in this study could indicate that the extrinsic pathway of the coagula-
tion cascade was not adequately activated in the current test model. The extrinsic pathway is 
initiated by the combination of TF and FVII and clotting time with normal protein concentra-
tions is approximately 8.6 seconds [17]. In the used test model the blood flowed through the 
material during 90 seconds. Under the influence of heparin which inhibits thrombin and fac-
tor Xa this time period might have been too short [18]. Another explanation could be that the 
applied rFVIIa was flushed out of the PU foam by the blood and therefore did not contribute 
to the coagulation. The same could be true for the other applied substances which gave no 
improved blood coagulation. Another explanation is that the complexity of the coagulation 
cascade might not be adequately resembled in vitro. This process was further complicated by 
the necessary addition of heparin which inhibits the coagulation cascade [18]. 
The PU foams which have been enriched with phospholipids, adenosine diphosphate and 
thrombin gave no improved results. With the addition of thrombin to a local hemostatic 
agent good results have been achieved in in vivo studies [19,20].
The good results of collagen in this study could be explained by its action mechanism which 
is based predominantly on platelet aggregation. Collagen-based hemostats attract platelets 
when they get in contact with blood. The platelets adhere to collagen fibrils and degranulate, 
thereby triggering platelet aggregation [21]. 
The improved results of PU foam after modification of the PEG concentration could indicate 
that this enhanced the attraction of platelets. In a study by Lee et al. [22] the platelet adhe-
sion to a PU surface increased slightly when short PEG chains were added whereas long PEG 
chains prevented platelet adhesion. The absorbable properties of PEG might contribute to its 
hemostatic effect by concentration of the endogenous coagulation factors and platelets. The 
effect of cellulose- and polysaccharide-based hemostats is based partly on this mechanism 
[17,23].
To analyse the influence of adding fluids to the foam some PU foams have been enriched 
with saline. As expected these foams gave no improved results compared to the PU foam 
without modifications. 
The treatment of PU foams with glow discharge led to significantly better results. This should 
be contributed to the electrostatic charge at the membrane surface which creates a more 
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hydrophilic material. By increasing the hydrophilicity of polyethylene Spijker et al. [10] found 
more platelet adhesion and activation of the clotting system. In 23 out of the 308 tests the 
blood took more than 14 seconds to reach the material and therefore the results from these 
tests were excluded. The delay in blood flow could be due to obstruction of the 200 µm 
needle.
An advantage of our in vitro model was the easy way to test the efficacy of a large number 
of modifications in multifold experiments with human blood. A few drawbacks of the in vitro 
model were also demonstrated. Generation of thrombin after collection of blood can lead 
to activation of platelets and subsequent loss of response to agonists [24]. The addition of 
heparin to the blood does not completely block the generation of thrombin in vitro [25]. This 
is supported by the results of the TAT generation test. The TAT concentration in blood before 
contact with any hemostatic agent showed a 1000-fold increase compared to normal blood. 
The lowering blood temperature might also have contributed to a diminished platelet func-
tion [26].
Conclusions
In this in vitro coagulation study the best results were achieved with collagen. Increase of the 
PEG concentration improved the results of PU foam significantly and seems a promising ap-
proach. There were no significant differences between this modified polyurethane foam and 
gelatin. The results of collagen however, could not be matched. Additional in vivo studies will 
have to be implemented to assess the application of polyurethane foam as a local hemostatic 
agent.
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Topical hemostatic agents are used in all surgical disciplines. Most of these hemostats are 
based on animal derived products like collagen and gelatin. They carry the potential risk of 
pathogen transmission. A newly developed biodegradable, fully synthetic hemostatic agent 
based on polyurethane foam (PU) with 55 wt% polyethylene glycol (PEG) would prevent 
these potential risks.
The hemostatic efficacy of this new agent was compared to gelatin and collagen in humans 
who underwent extraction of an upper and lower molar (split-mouth model). After extraction 
of a molar in the maxilla and mandible a PU foam and collagen or gelatin was inserted in the 
extraction socket for two minutes. Hereafter the agents were removed and stored in EDTA to 
stop coagulation. Then the concentration of coagulation parameters thrombin-antithrombin 
III (TAT) complexes, fibrinogen and thromboxane B2 (TxB2) in blood extracts from the agents 
was measured. The concentrations were also determined in baseline blood samples which 
were collected from the extraction socket.
The concentrations of TAT and TxB2 were significantly increased and fibrinogen concentra-
tion was significantly reduced compared to baseline wound blood concentrations indicating 
enhanced hemostasis. No significant differences were seen in the concentrations of these 
coagulation parameters in the three different hemostatic agents. 
These results show that PU combined with 55 wt% PEG is a promising alternative for the 




Topical hemostatic agents are used in all surgical disciplines. Most of the mechanical hemo-
stats are based on animal derived products like collagen and gelatin. Therefore, they carry the 
potential risk of pathogen transmission which can result in diseases like Creutzfeld-Jacob or 
Bovine Spongiform Encephalopathy (BSE) [1]. 
A newly developed fully synthetic hemostatic agent would avoid these potential risks. Fur-
thermore, the production process of a synthetic material allows greater control over material 
properties and tissue responses, which gives a synthetic material another advantage over 
animal derived products [2]. The animal derived hemostatic agents are relatively cheap ma-
terials. Therefore, a new synthetic topical hemostatic agent should preferably be made of a 
material that can be produced at the same low cost. 
A blend of modified polyurethane foam (PU) and polyethylene glycol (PEG) was processed to 
a synthetic, biodegradable material with possible hemostatic properties. The biodegradability 
and biocompatibility of a comparable PU has been demonstrated in a previous study [3]. In an 
animal study in which this PU foam was used to close oroantral communications, complete 
bony regeneration was seen after one year with only small PU fragments at a microscopic 
level [4]. This was a PU with 5 wt% PEG, whereas our PU with 55 wt% PEG will be resorbed 
much faster. The synthetic PU foam can be produced at low cost but the development of 
bioresorbable products has become expensive due to laws and regulations. Therewith, it can 
be expected that the PU will be more expensive than the collagen- and gelatin-based hemo-
static agents. 
When a biomaterial like PU comes into contact with blood, adsorption of factor XII initiates 
the contact activation pathway of the coagulation cascade and leads to platelet adhesion 
and activation [5]. The hemostatic efficacy of this material was improved by increasing the 
concentration of PEG up to 55 wt% as shown by in vitro study [6]. Hemostasis, however, is 
complex and difficult to resemble in vitro [7]. Therefore, an in vivo study was performed in 
which the polyurethane foam was compared with a commercially available collagen- and 
gelatin-based hemostatic agent. The purpose of this study was to investigate if the modified 
PU could achieve similar results as the collagen- and gelatin-based hemostatic agents. The 
hemostatic efficacy of the materials was analysed by measurement of blood coagulation pa-
rameters. Thrombin-Antithrombin III (TAT) complexes, fibrinogen and thromboxane B2 (TxB2) 
were measured in blood which was derived out of the materials after use in a human wound.
The concentration of TAT complexes is accepted as an index of thrombin generation in vivo 
and thus a measurement for the amount of coagulation [8]. Fibrinogen is converted into 
fibrin by thrombin [9]. Reduction of fibrinogen is therefore also an indicator of the amount of 
coagulation. Thromboxane B2 is an inactive metabolite of thromboxane A2 which can be used 




The study population consisted of sixty patients who were referred to the Department of Oral 
and Maxillofacial Surgery of the University Hospital Groningen, the Netherlands, for extrac-
tion of an upper and lower molar. The molars were extracted because of insufficient space in 
the dental arch or because they were difficult to clean for the patient. None of the patients 
had an active pericoronitis or periodontal disease during the time of extraction. The patients 
were otherwise healthy and none of them used any medication. The study protocol was ap-
proved by the local ethical committee and conducted according to the guidelines for good 
clinical practice and the declaration of Helsinki. Written informed consent was obtained from 
each patient before inclusion.
Materials
In this study PU foam was compared to a collagen and gelatin hemostatic agent. The used 
PU was a block-copolymer composed of urethane hard segments and co-polyether-ester 
soft segments. The soft segments (total molecular weight: 2.000 g/mol) consisted of 50% 
DL-lactide and 50% ε-caprolactone. PEG 1.000 was used as initiator for the soft segments 
synthesis, and after that PEG 20.000 was added in a mass ratio of 3 (first PU formulation) to 
1 (PEG 20.000) to prepare a blend. The urethane segments were synthesized with 1,4-bu-
tanediisocyanate (BDI) and 1,4-butanediol (BDO). They had a uniform length of 5 urethane 
moieties, which resulted in a PU with BDI-BDO-BDI-BDO-BDI urethane segments in the 
polymer. The PU was then dissolved in 1,4-dioxane. After dissolving, the solution was poured 
into a mold and cooled down to −18°C. The solution was freeze-dried at 3 mbar to remove 
the 1,4-dioxane crystals, resulting in an highly porous foam with a porosity of 97% and an 
overall PEG-content of 55 wt%. Overall porosity was calculated after determining the weight 
and dimensions of the foams. The foams had a cylindrical shape with a size of 1 cm3 and were 
ultimately sterilized using ethylene oxide. The polymers and foams were manufactured by 
Polyganics BV (Groningen, the Netherlands).
For the collagen hemostat, Hémocollagène (absorbable collagen hemostat; Septodont, Saint-
Maur-des-Fossés, France) was used with a size of 1 cm3. For the gelatin hemostat, Spongo-
stan (absorbable gelatin sponge; Johnson&Johnson, Skipton, United Kingdom) was used with 
a size of 1 cm3. 
Study protocol
We designed an experimental, prospective, randomized, split mouth protocol in which PU 
foam, collagen and gelatin were tested. Randomisation was generated with a computer ran-
dom number generator. PU foam was tested in all patients and compared to a collagen or 
gelatin sponge in random order. After extraction of the lower molar, 0.2 ml of blood was 
collected from the extraction socket with a syringe. The blood was stored in a cup with 200 
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µl of 0.2 M ethylenediaminetetraacetic acid (EDTA) solution to chelate calcium and prevent 
further activation of coagulation proteins [11]. 
Hereafter, one of the test materials was inserted in the alveolus during two minutes. After 
extraction of the upper molar another test material was inserted in this alveolus for two 
minutes. Continuous suction was performed around the alveolus to ensure that saliva did 
not flow in the alveolus. After the two minutes had passed, each material was stored in a cup 
filled with EDTA solution. The amount of EDTA solution was adjusted for each test material 
to match the mean amount of blood that was absorbed by each material. In the cups for the 
PU foams 250 µl of EDTA solution was inserted, for the collagen sponge 170 µl and for the 
gelatin sponge 160 µl. Thus, the ratio of blood:EDTA solution was kept at 1:1. 
The cups with blood and materials were centrifuged at 13.000 revolutions per minute (rpm) 
during 1 minute in a MSE Micro Centaur. This causes the plasma, cellular release products 
and EDTA solution to poor out of the foams. The aliquots of plasma were collected and stored 
at -80°C. The samples were thawed just before analysis.
TAT complex immunoassays
The plasma samples were diluted 1 in 1000 in dilution buffer (0.1% BSA in PBS pH 7.4). 
Hereafter, the samples were assayed for TAT complexes using a commercially available im-
munoassay kit (Enzygnost TAT micro; Behring Diagnostics, Westwood, MA). This assay is a 
sandwich enzyme linked immunosorbent assay (ELISA).
Fibrinogen immunoassays
Thirty paired plasma samples were subjected to the detection of fibrinogen. The plasma 
samples were diluted 1 in 5000 in dilution buffer. Fibrinogen was measured with an ELISA 
(Enzyme Research Laboratories Ltd, South Bend, IN, USA).
Thromboxane B2 immunoassays
TxB2 generation was measured in plasma samples diluted 1 in 1000 in dilution buffer using 
immunoassay (Cayman Chemical, Ann Arbor, MI, USA) as indicated by the manufacturer’s 
protocol.
Statistical analysis
Data were analyzed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as 
mean and standard deviation (SD). The results for the group of 30 patients who received PU 
and gelatin were analysed separately from the group of 30 patients who received PU and col-
lagen. The paired samples were analyzed with a Wilcoxon’s signed rank test. 
Linear regression analysis was used to determine the relationship between extraction time 
and baseline values. A two-sided p-value < 0.05 was considered statistically significant.
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Results
Sixty patients (33 male, 27 female) with a mean age (range) of 26 (19-47) were included in 
the study. To analyse the degree of coagulation in the different samples we measured the 
concentration of TAT complexes, fibrinogen and TxB2. We found that the use of test materials 
significantly increased the concentration of TAT complexes and TxB2 compared with baseline 
values. The fibrinogen was decreased significantly compared with baseline values. Moreover, 
we found that baseline values, obtained from wound blood, were significantly different from 
reported normal blood values. In this wound blood, TAT and TxB2 were markedly increased 
and fibrinogen decreased.
The results were separately analysed for the two groups of 30 patients and are therefore 
shown in different bar charts. Figure 1 shows the TAT concentration for the different test 
materials and baseline samples. 
The mean TAT concentrations for PU (1.01 ± 0.29 µg/ml) and collagen (0.96 ± 0.30 µg/ml) 
were higher than the baseline concentration of 0.52 ± 0.20 µg/ml (p < 0.001) in this group. 
Between PU and collagen there was no significant difference (p = 0.13).
The concentrations of TAT complexes in the group with PU and gelatin were 0.97 ± 0.20 
µg/ml and 1.03 ± 0.27 µg/ml respectively. Therewith, the concentrations were significantly 
higher than the mean concentration of TAT complexes in the baseline samples which was 
0.57 ± 0.19 µg/ml (p < 0.001). Between PU and gelatin there were no significant differences 
in concentration of TAT complexes (p = 0.30).
Figure 2 shows the results for the fibrinogen concentration of the test materials and baseline 
samples. 
Figure 1. Mean (± SD) thrombin-antithrombin III concentration for the different test materials and baseline 
































































The mean concentration of fibrinogen in PU (0.16 ± 0.11 mg/ml) and collagen (0.14 ± 0.12 
mg/ml) was significantly lower than the mean concentration of fibrinogen in the baseline 
samples (0.50 ± 0.24 mg/ml) with a p value < 0.001 for this group. Between PU and collagen 
no significant differences were seen for the concentration of fibrinogen (p = 0.88). 
In the other group the fibrinogen concentration was also significantly lower in PU (0.16 ± 
0.24 mg/ml) and gelatin (0.16 ± 0.17 mg/ml) than in the baseline blood samples (0.51 ± 
0.30 mg/ml) with a p-value < 0.001. The fibrinogen concentration was not significantly dif-
ferent between PU and gelatin (p = 0.49).
To investigate the influence of the test materials on platelet aggregation the TxB2 concentra-
tion was measured. In figure 3 the data for the two groups is presented.
The mean concentration of TxB2 in the first group was 28.5 ± 24.3 ng/ml for the PU and 20.3 
± 17.5 ng/ml for the collagen. This was significantly higher than the mean concentration of 
8.5 ± 4.3 ng/ml in the baseline samples (p < 0.001). Between PU and collagen the concen-
tration of TxB2 was not significant (p = 0.16).
The mean concentration of TxB2 in the second group was 31.9 ± 20.0 ng/ml for the PU and 
28.8 ± 22.5 ng/ml for the gelatin. This was again significantly higher than the mean con-
centration of 7.7 ± 4.6 ng/ml in the baseline samples (p < 0.001). No significant differences 
were seen between the TxB2 concentrations for PU and gelatin (p = 0.70).
The extraction time for the molars varied in the different subjects ranging from 2 to 15 
minutes with a mean extraction time of 6.8 minutes. To investigate if the extraction time 
correlated with the baseline concentrations of TAT complexes, fibrinogen and TXB2 a linear 
regression analysis was performed. This analysis revealed that the extraction time was not 
correlated with the baseline concentrations of TAT complexes, fibrinogen and TxB2 (Table 1).
Figure 2. Mean (± SD) fibrinogen concentrations for the different test materials and baseline samples. PU: 










































Our study examined the hemostatic efficacy of modified polyurethane foam by measuring 
different coagulation parameters in a human model. The coagulation parameters showed no 
differences between the PU foam and gelatin- or collagen-based materials. The differences 
between the parameters measured from the test materials and the baseline values how-
ever, were significant, indicating that all tested materials substantially increased hemostasis 
supplementary to the activation induced by the wound area.
A lot of research has been done on the hemostatic properties of biomaterials like polyure-
thane [5, 12, 13]. The polyurethane foam we tested was combined with 55 wt% PEG to 
increase the absorbing properties of the foam. The higher absorbability should increase the 
concentration of endogenous coagulation factors and platelets. The hemostatic effect of cel-
lulose- and polysaccharide-based hemostatic agents is partially based on this mechanism 
[14, 15].
We used a human in vivo model in which it is possible to compare different hemostatic agents 
in similar wounds. The use of extraction sockets of upper and lower molars has the advantage 
that the test materials could be analysed under similar conditions within the same patient. 
We used coagulation parameters to determine hemostatic efficacy because time to hemo-
stasis could not be accurately measured in this split mouth model. This could be considered 
a drawback as time to hemostasis is the most essential parameter.
The different structures of the test materials made it impossible to ensure complete blinding 
of the surgeons. We do not expect that this has influenced the results because the time in the 
wound was exactly 2 minutes for all test materials and the parameter values were measured 
by ELISA. Because the outcome of the ELISA was determined on numerical coded samples by 
computer measurement, the possible bias was restricted to a minimum for both surgeons 
and researchers.
We compared the PU foam with a collagen and gelatin hemostatic agent. These agents are 
together with oxidized regenerated cellulose traditionally the most widely used hemostatic 
agents in surgery [16]. They promote platelet aggregation and coagulation by providing a 
Table 1. Regression analysis of the correlation of extraction time with the baseline concentrations 
of TAT complexes, fibrinogen en TxB2.
Coagulation parameter β value Standard Error p-value
TAT complexes -0.004 0.003 0.19
Fibrinogen -0.002 0.003 0.57
TxB2 -0.005 0.004 0.29
TAT: thrombin-antithrombin III, TxB2: thromboxane B2, β: regression coefficient.
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three-dimensional meshwork for clotting to take place [17]. The oxidized regenerated cel-
lulose was not tested in this study because the structure of the material made it impossible 
to obtain plasma samples after centrifugation. 
There is no consensus on which of these materials is the best hemostatic agent [18, 19], 
although some studies indicated that collagen is more effective than gelatin and oxidized 
regenerated cellulose [20, 21]. In this study no differences were seen in efficacy between the 
materials. The study design is unsuitable for comparison between collagen and gelatin but 
the differences appear to be minimal.
The mean baseline concentrations for the different coagulation parameters show great dif-
ferences from the mean concentrations that are reported for circulating blood. The mean 
concentration of TAT complexes in circulating blood is 1.0 - 4.1 µg/L [22], whereas we found 
a mean baseline concentration of 0.55 µg/ml which is roughly 500 times higher. The mean 
baseline concentration of fibrinogen we found in this study is 0.51 mg/ml and therewith six 
times lower than the mean concentration in circulating blood of 3.0 mg/ml that is reported 
in the literature [23]. For TxB2 the maximal estimate of the circulating concentration is 2.0 
pg/ml [24]. The mean concentration of 8.1 ng/ml that we found in the baseline samples is 
4000 times higher. These differences are due to activation of the coagulation cascade in vivo 
as the baseline blood was collected from a wound [9]. For this study these differences are of 
minor importance as every test was performed in a wound situation.
The extraction time could theoretically influence the baseline values as there is more time for 
the coagulation cascade to be completed. In our results we did not find a correlation between 
extraction time and baseline concentrations. This could be due to constant blood flow from 
the wound thus preventing a higher baseline value when the extraction time was longer. 
Another explanation would be that maximum baseline value was already reached after two 
minutes, which was the shortest extraction time.
Figure 3. Mean (± SD) thromboxane B2 concentrations for the different test materials and baseline samples. 















































The mouth is known as a fibrinolytic environment predominantly due to the saliva [25]. 
During our tests the influence of saliva was minimal due to continuous suction around the 
alveolus and furthermore equal for all tests. Therefore, this factor is not expected to have 
influenced the test results.
For this study only healthy subjects were included. The future use of the PU foam will be in 
patients with an impaired hemostasis. Future studies will have to show if the hemostatic effi-
cacy of PU is strong enough to achieve complete hemostasis in those compromised patients. 
Further research should therefore also aim on improvement of the hemostatic efficacy of the 
PU. This could be done by combining the PU with a procoagulant substance. 
Conclusions
In this study PU foam was compared with collagen and gelatin for its hemostatic efficacy in a 
human model. In this model, PU foam showed a similar hemostatic efficacy as the collagen 
and gelatin hemostatic agents. The synthetic PU is therefore a promising alternative for the 
nowadays used, animal derived, hemostatic agents.
Acknowledgements
The authors gratefully acknowledge R. de Graaf, J. Jankie and B.C. Bhat for the development 
and production of the PU foams. We thank Dr. J.J.R. Huddleston Slater for his contribution to 
the study design.





[1] Nemoto T, Horiuchi M, Ishiguro N, 
Shinagawa M (1999) Detection methods of 
possible prion contaminants in collagen and 
gelatin. Arch Virol 144(1):177-84. 
[2] Lutolf MP, Hubbell JA (2005) Synthetic 
biomaterials as instructive extracellular 
microenvironments for morphogenesis in 
tissue engineering. Nat Biotechnol 23(1):47-
55. 
[3] van Minnen B, van Leeuwen MB, 
Kors G, Zuidema J, van Kooten TG, 
Bos RR (2008) In vivo resorption of a 
biodegradable polyurethane foam, based 
on 1,4-butanediisocyanate: A three-year 
subcutaneous implantation study. J Biomed 
Mater Res A 85(4):972-82. 
[4] Visscher SH, van Minnen B, van Leeuwen 
MB, van Kooten TG, Bos RR (2009) 
Closure of oroantral communications using 
biodegradable polyurethane foam: a long 
term study in rabbits. J Biomed Mater Res B 
91(2):957-63.
[5] Gorbet MB, Sefton MV (2004) Biomaterial-
associated thrombosis: Roles of coagulation 
factors, complement, platelets and 
leukocytes. Biomaterials 25(26):5681-703. 
[6] Broekema FI, van Oeveren W, Zuidema J, 
Visscher SH, Bos RR (2011) In vitro analysis 
of polyurethane foam as a topical hemostatic 
agent. J Mater Sci Mater Med 22(4):1081-6. 
[7] Furie B, Furie BC (2007) In vivo thrombus 
formation. J Thromb Haemost 1:12-17
[8] Pelzer H, Schwarz A, Heimburger N 
(1988) Determination of human thrombin-
antithrombin III complex in plasma with 
an enzyme-linked immunosorbent assay. 
Thromb Haemost 59(1):101-6. 
[9] Davie EW, Fujikawa K, Kisiel W (1991) The 
coagulation cascade: Initiation, maintenance, 
and regulation. Biochemistry 30(43):10363-
70. 
[10] Kamath S, Blann AD, Lip GY (2001) Platelet 
activation: Assessment and quantification. 
Eur Heart J 22(17):1561-71. 
[11] Monroe DM, Hoffman M, Oliver JA, Roberts 
HR (1997) Platelet activity of high-dose 
factor VIIa is independent of tissue factor. Br 
J Haematol 99(3):542-7. 
[12] Skarja GA, Brash JL (1997) Physicochemical 
properties and platelet interactions of 
segmented polyurethanes containing 
sulfonate groups in the hard segment. J 
Biomed Mater Res 34(4):439-55. 
[13] Elwing H (1998) Protein absorption and 
ellipsometry in biomaterial research. 
Biomaterials 19(4-5):397-406. 
[14] Thatte HS, Zagarins SE, Amiji M, Khuri SF 
(2004) Poly-N-acetyl glucosamine-mediated 
red blood cell interactions. J Trauma 57(1 
Suppl):S7-12. 
[15] Kanko M, Liman T, Topcu S (2006) A 
low-cost and simple method to stop 
intraoperative leakage-type bleeding: Use 
of the vancomycin-oxidized regenerated 
cellulose (ORC) sandwich. J Invest Surg 
19(5):323-7. 
[16] Schonauer C, Tessitore E, Barbagallo G, 
Albanese V, Moraci A (2004) The use of local 
agents: Bone wax, gelatin, collagen, oxidized 
cellulose. Eur Spine J 13 Suppl 1:S89-96. 
[17] Palm MD, Altman JS (2008) Topical 
hemostatic agents: A review. Dermatol Surg 
34(4):431-45. 
[18] Hong YM, Loughlin KR (2006) The use of 
hemostatic agents and sealants in urology. J 
Urol 176(6 Pt 1):2367-74. 
[19] Msezane LP, Katz MH, Gofrit ON, Shalhav 
AL, Zorn KC (2008) Hemostatic agents and 
instruments in laparoscopic renal surgery. J 
Endourol 22(3):403-8. 
[20] Alexander JM, Rabinowitz JL (1978) 
Microfibrillar collagen (avitene) as a 
hemostatic agent in experimental oral 
wounds. J Oral Surg 36(3):202-5. 
[21] Wagner WR, Pachence JM, Ristich J, 
Johnson PC (1996) Comparative in vitro 
analysis of topical hemostatic agents. J Surg 
Res 66(2):100-8. 
[22] Jorgensen LN, Lind B, Hauch O, Leffers A, 
Albrecht-Beste E, Konradsen LA (1990) 
Thrombin-antithrombin III-complex & fibrin 
44
degradation products in plasma: Surgery 
and postoperative deep venous thrombosis. 
Thromb Res 59(1):69-76. 
[23] Kannel WB, Wolf PA, Castelli WP, 
D’Agostino RB (1987) Fibrinogen and risk 
of cardiovascular disease. the framingham 
study. JAMA 258(9):1183-6. 
[24] Patrono C, Ciabattoni G, Pugliese F, Pierucci 
A, Blair IA, FitzGerald GA (1986) Estimated 
rate of thromboxane secretion into the 
circulation of normal humans. J Clin Invest 
77(2):590-4. 
[25] Albrechtsen OK, Thaysen JH (1955) 
Fibrinolytic activity in human saliva. Acta 





Comparison of topical hemostatic agents 
in a rat tail tip model
Submitted
Ferdinand I. Broekema




A broad variety of topical hemostatic agents are used in the surgical disciplines. We analysed 
the most widely used topical hemostatic agents and compared them to a newly developed, 
synthetic topical hemostatic agent based on polyurethane (PU). Furthermore, we tested PU 
enriched with the procoagulant substance chitosan to evaluate if this could increase its he-
mostatic efficacy.
The following topical hemostatic agents were compared using a rat tail tip model: Collagen, 
gelatin, oxidized regenerated cellulose, chitosan dressing, PU and PU with chitosan. The tail 
tip was fixated on a developed test device to ensure a constant and equal pressure of the test 
material on the wound. The mean bleeding time was determined and compared between 
the groups.
PU showed a mean bleeding time of 23.9 minutes. This was not significantly shorter or lon-
ger than gelatin (23.6 min), collagen (28.2 min) or oxidized regenerated cellulose (26.9 min). 
The addition of chitosan to PU did lead to the shortest mean bleeding time (21.5 min) but 
this was not significantly faster than PU without chitosan.
These results show that PU is a promising alternative for the most widely used topical hemo-
static agents. Future studies will have to show if the addition of procoagulant substances like 




Many different topical hemostatic agents are used in the surgical disciplines. The most widely 
used agents are collagen, gelatin and oxidized regenerated cellulose (ORC). There is no con-
sensus on which of these agents has the best hemostatic efficacy and each product has 
significant potential drawbacks. As a result, none of the products has become dominant over 
the other topical hemostatic agents [1].
A disadvantage of collagen and gelatin hemostatic agents is that they are animal derived and 
therefore carry the potential risk of pathogen transmission. The ORC can lead to inflamma-
tion of surrounding tissue and delay wound healing because of its low pH [2].
A newly developed fully synthetic topical hemostatic agent with a good biocompatibility could 
avoid these potential risks. Polyurethane (PU) is a synthetic, biodegradable material with 
good biocompatible properties [3]. The hemostatic capacity of this material was increased 
in an in vitro study by combining it with a high percentage of polyethylene glycol (PEG) [4]. 
Coagulation is initiated by platelets that adhere to the PU surface while the PEG enhances the 
absorbable properties of the PU which increases the concentration of the endogenous co-
agulation factors and platelets. The hemostatic effect of cellulose- and polysaccharide-based 
hemostatic agents is partially based on this mechanism [5,6]. Furthermore, PEG increases 
the hydrophilicity of the material and the greater volume of water within the polyurethane 
can allow for a greater amount of hydrolysis, and thus degradation, to take place [7,8]. The 
PU can be formulated into membranes and foams that can be directly applied to the wound 
surface. 
In this study, the hemostatic efficacy of a PU foam was compared to a collagen, gelatin and 
ORC material in a standardized rat model. This was done to analyse the hemostatic efficacy 
of the new material compared to the most widely used hemostatic agents.
To analyse if this new hemostatic agent could be improved by adding a procoagulant sub-
stance, tests were also performed with PU combined with synthetic chitosan which is also 
known as Poly D-Glucosamine. Chitosan is the deacetylated form of chitin (poly-N-acetyl 
glucosamine). Both substances have a similar hemostatic action mechanism which is be-
lieved to result from mechanical sealing, vasoconstriction and the mobilization of erythro-
cytes, clotting factors and platelets to the site of the injury [9,10]. HemCon is a chitosan 
dressing (CD) and was also investigated to analyse if these results would match the PU with 
chitosan. HemCon is a relatively new hemostatic agent that has shown a good hemostatic 
efficacy in humans [11,12].
The materials were compared with each other using a previously described rat tail-tip model 
[13,14]. In this model the tail was transected at 5 mm from the tip and the test materials 




The study was approved by the Committee for Animal Experiments (University of Groningen, 
the Netherlands). Eighty male adult Wistar rats weighing 200 to 300 grams were obtained 
from Charles River, the Netherlands. The animals had unrestricted access to food and water.
Materials
Tests were performed with seven different test materials. 
Hémocollagène (absorbable collagen hemostat; Septodont, Saint-Maur-des-Fossés, France) 
foams (1 cm3) were used as collagen hemostatic agent. 
Spongostan (absorbable gelatin foam; Johnson&Johnson, Skipton, United Kingdom) foams (1 
cm3) were used as gelatin hemostatic agent. 
Surgicel (absorbable oxidized regenerated cellulose; Ethicon, Neuchâtel, Switzerland) knitted 
fabric (1.25 cm x 5 cm) was used as ORC hemostatic agent.
HemCon (chitosan-based wound dressing; HemCon Medical Technologies, Inc, Portland, 
Oregon, USA) was used as CD hemostatic agent. 
Sterilux (sterile gauze compression bandages; Hartmann, Heidenheim, Germany) gauze pads 
(5 cm x 5 cm) were used as control agent. 
The tested PU was a block-copolymer composed of urethane hard segments and co-poly-
ether-ester soft segments. The soft segments (total molecular weight: 2.000 g/mol) con-
sisted of 50% DL-lactide and 50% ε-caprolactone. PEG 1.000 was used as initiator for the 
soft segments synthesis, and after that PEG 20.000 was added in a mass ratio of 3 (first PU 
formulation) to 1 (PEG 20.000) to prepare a blend. The urethane segments were synthesized 
Figure 1. Schematic picture of the test device that was used to compare the different test materials. The 
tail was fixated on the platform on the left. The test material was placed in the sliding device in the mid-




with 1,4-butanediisocyanate (BDI) and 1,4-butanediol (BDO). They had a uniform length of 5 
urethane moieties, which resulted in a PU with BDI-BDO-BDI-BDO-BDI urethane segments 
in the polymer. The PU was then dissolved in 1,4-dioxane. After dissolving, the solution was 
poured into a mold and cooled down to −18°C. The solution was freeze-dried at 3 mbar to 
remove the 1,4-dioxane crystals, resulting in an highly porous foam with a porosity of 97% 
and an overall PEG-content of 55 wt%. Overall porosity was calculated after determining the 
weight and dimensions of the foams. 
The PU foams with chitosan were made in the same way except for the addition of chitosan 
powder. After the PEG 20.000 was added, chitosan powder was added to the blend resulting 
in PU foams with a concentration of 50 mg chitosan per foam. 
The PU foams had a cylindrical shape with a size of 1 cm3 and were ultimately sterilized using 
ethylene oxide. The polymers and foams were manufactured by Polyganics BV (Groningen, 
the Netherlands).
Test device
A test device was developed for this test to ensure a constant and equal pressure of the test 
material on the wound (Figure 1). This test device consisted of a metal plate (30 cm x 15 cm 
x 2 cm) on which the tail of the rat and the test material could be fixated. The test material 
was placed on a sliding device on the metal plate. A weight of 155 g was attached to the 
sliding device via a pulley to ensure that a constant pressure would be applied to the wound. 
The weight created a constant pressure of 0.29 N/mm2 that was applied to the wound. This 
was calculated out of the mass (0.155 kg) and acceleration of gravity (9.813 m/s2), which 
gave a force of 1.521 N (0.155 * 9.813). This force was divided through the mean bleeding 
area of the wound (5.31 mm2) which led to a pressure of 0.29 N/mm2 (2.9 * 105 Pa). For this 
calculation we assumed that the friction in the device was negligible.
Study protocol
The eighty rats were randomly assigned to one of eight test groups of 10 animals each. From 
the eight test groups, seven were treated with a test material and one served as a nega-
tive control group and received no treatment. The tested materials were collagen, gelatin, 
oxidized regenerated cellulose, a chitosan dressing, gauze, PU foam and PU foam combined 
with chitosan.
The animals were anesthetized by inhalation of 5% isoflurane and weighed before surgery. 
During the surgery anesthesia was maintained by inhalation of 2-2.5% isoflurane. The ani-
mals were placed in a prone position on a platform with their tails resting 10 cm below the 
surface on the test device. A warming mat was placed under the rat to keep the temperature 
of the rat at 37° C. The rat tail was fixated on a platform on the developed test device with 
tape. The tail tip was placed 7 mm over the edge of the platform and transected at 5 mm 
from the tip. The mean diameter of the tail tip was 2.6 mm (SD: 0.24) and the mean weight 
of the transected tail-tip was 0.016 g (SD: 0.003).
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After transection of the tail, the test material was applied to the wound during three minutes. 
After three minutes the test material was removed and the wound was blotted with filter pa-
per. This was repeated every minute until no blood was observed on the paper upon blotting. 
The time from the tail transection to the bleeding cessation was the bleeding time. During 
the experiment the tested material was replaced by a fresh one every ten minutes to prevent 
that the materials got fully saturated with blood and consequently might loose their hemo-
static effect. After completion of the experiments, the animals were sacrificed by intravenous 
administration of 0.5 ml of pentobarbital sodium (200 mg/ml).
Statistical analysis
Statistical analysis was performed using SPSS 20.0. The mean bleeding time of PU was com-
pared to the other materials with the Mann-Whitney-U-test. Using the Bonferroni correction 
a p value less than (0.05/5=) 0.01 was considered statistically significant. For the second 
comparison including the PU with chitosan a p value less than (0.05/3=) 0.017 was consid-
ered statistically significant. 
The hemostatic agents collagen, gelatin, ORC and CD were compared using a Kruskal-Wallis 
test. A p value less than 0.05 was considered statistically significant for this test.
Results
The mean bleeding time and standard deviation was calculated per material and presented 
in table 1 in order of efficacy.
PU was first compared to collagen, gelatin, ORC, gauze and the control group without ma-
terial. This showed that the bleeding time of PU was not significantly different from colla-
gen (p=0.24), gelatin (p=0.70) and ORC (p=0.27). The difference with gauze and the control 
group without material was significant with a p value < 0.001 (Figure 2). 
Table 1. Mean bleeding time and standard deviation of the tested materials in order of efficacy. 
Material Mean bleeding time (min) Standard deviation







No material 54,5 4,86
PU, polyurethane; ORC, oxidized regenerated cellulose; CD, chitosan dressing
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Figure 3. Schematic representation of the mean bleeding time and standard deviation for PU with and 


























Figure 2. Schematic representation of the mean bleeding time and standard deviation for the different 






































PU was also compared to the PU that was combined with chitosan to analyze if this would 
improve the hemostatic efficacy. Furthermore, the chitosan dressing (CD) HemCon was in-
cluded in this comparison to evaluate how this material would relate to the PU with chitosan 
(Figure 3). The bleeding times of PU with and without chitosan were not significant (p=0.27). 
The difference between PU and CD was also not significant (p=0.13). The PU with chitosan 
did have a significantly shorter bleeding time than CD with a p value of 0.004. The differences 
between collagen, gelatin, ORC and CD were not significant (p=0.14).
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Discussion
This study was done to compare the hemostatic efficacy of the most widely used topical he-
mostatic agents with a newly developed synthetic hemostatic agent based on polyurethane. 
Tests were also performed with the polyurethane hemostatic agent combined with chitosan 
to analyse if the hemostatic efficacy could be improved by adding a procoagulant substance. 
We found that the mean bleeding time of PU was not significantly longer or shorter than 
the most widely used topical hemostatic agents. The addition of chitosan to PU did lead to 
a shorter mean bleeding time but this difference was however not significant compared to 
the standard PU foam. Thus, the addition of chitosan to the PU foam could not improve its 
hemostatic efficacy. 
Previous studies on the hemostatic efficacy of widely used topical hemostatic agents showed 
various results. A number of studies concluded that the hemostatic agents had comparable 
results [15-17]. Several studies found collagen to be the most effective topical hemostatic 
agent [4,18,19]. Other studies pointed out chitin as the most effective topical hemostatic 
agent [20],[1,21].
Our study also showed no clear favourite amongst the tested topical hemostatic agents. The 
addition of chitosan to the PU foam could not improve its hemostatic efficacy. This could be 
caused by mixing the chitosan through the foam. As a result the chitosan concentration at 
the surface of the foam might not have been high enough to exert an additional effect. Future 
studies with a higher concentration of chitosan or a layer of chitosan at the surface will have 
to show if the addition of chitosan is a possibility to increase the hemostatic efficacy of PU. 
The chitosan-based dressing HemCon showed a significantly longer bleeding time than the 
PU foam with chitosan. This might be explained by the hemostatic action mechanism of 
HemCon. The product becomes sticky upon contact with blood and creates an enhanced tis-
sue adhesion [22]. In the used test model, the hemostatic agent had to be removed from the 
wound regularly to analyse if the wound was dry. The sticky property of the chitosan could 
have led to partial removal of the blood clot and thus a longer bleeding time. 
Our bleeding model was modified from other studies [13,14]. The most important change 
was the use of a test device that was developed for this purpose. The test device ensured 
a constant pressure to the wound that was equal for all test materials. This is a major im-
provement because compression by the researcher inevitably leads to varying pressure to 
the wound. The removal of the tail at 5 mm from the tip led to a wound diameter with a low 
standard deviation and thus to comparable and reproducible wounds.
A drawback of this model was that the hemostatic agent had to be removed every minute to 
check if the wound was dry. This method implied that a part of the blood clot was removed 
every time the wound was checked. This effect was equal for all test materials but might have 




The PU foam showed a comparable mean bleeding time as the widely used hemostatic 
agents in this model. The PU combined with chitosan showed the shortest mean bleeding 
time but this was not significantly different from PU. We conclude that PU is a promising 
alternative for the most widely used topical hemostatic agents. Future studies will have to 
show if the addition of procoagulant substances like chitosan can significantly improve the 
hemostatic efficacy of PU.
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For most topical hemostatic agents the mechanism of hemostatic action is not fully under-
stood. This work aimed to investigate the hemostatic mechanism of action and viscoelastic 
properties of Polyurethane foam (PU) in comparison to the widely used collagen and gelatin.
The hemostatic mechanism of action of the materials was tested using human whole blood 
and platelet-poor plasma (PPP). The ability of the hemostatic agent to exert pressure on the 
wound was quantified in terms of its viscoelastic properties both under dry and wet condi-
tions using a low load compression tester (LLCT).
It has been shown that collagen and PU initiate hemostasis through both thrombocyte ag-
gregation and contact activation of the coagulation cascade. Gelatin did not show improved 
thrombocyte aggregation or initiation of the coagulation cascade compared to the negative 
control group. PU is more firm under wet conditions and shows more springback than col-
lagen and gelatin.
We conclude that PU is promising as a topical hemostatic agent because it initiates both the 
coagulation cascade and thrombocyte aggregation. Furthermore, it has favorable viscoelastic 




Topical hemostatic agents are often used to control bleeding within the different surgical 
disciplines. The mechanism of hemostatic action however, is not fully understood for most 
topical hemostatic agents. 
Under normal conditions, hemostasis is achieved by thrombocyte adherence to the suben-
dothelium and activation of the coagulation cascade by Tissue Factor (TF). The initial clot is 
formed by the thrombocytes while TF reacts with factor VII to activate factor X which further 
activates the coagulation cascade. This leads to the formation of fibrin and stabilization of 
the clot [1]. The coagulation cascade can also be activated when blood comes into contact 
with a negatively charged surface. This contact activation system is traditionally known as the 
intrinsic pathway [2].
When the natural hemostatic process in a patient is insufficient, hemostatic agents can be 
used to accomplish hemostasis. The most often used topical hemostatic agents include col-
lagen and gelatin. These hemostatic agents have different modes of action. For collagen, 
the mechanism of action is believed to be attraction and aggregation of thrombocytes. He-
mostatic agents based on gelatin provide a physical matrix in which a clot can form while 
absorbing surrounding fluids [3]. 
We have been studying the hemostatic efficacy of Polyurethane foam (PU) with uniform hard 
segments composed of butanediol and 1,4-butanediisocyanate and soft segments of DL-
lactide and ε-caprolactone combined with 55 wt% Polyethylene Glycol (PEG) [4,5]. In these 
studies we found that a high percentage of PEG increased the hemostatic capacity of PU and 
that the hemostatic efficacy of this material was comparable to collagen and gelatin hemo-
static agents. We also noticed that PU kept its shape and firmness after contact with blood 
while the collagen and gelatin became soft and mushy and thus provides less pressure to the 
wound. Therefore, we developed a test set-up to objectify these notifications.  
We hypothesize that the PU provides a surface to which thrombocytes can adhere and might 
initiate the coagulation cascade through contact activation. Furthermore, we expect that PU 
keeps its firmness and elasticity under wet conditions and thereby provides more pressure to 
the wound. The aim of the current study is to test our hypothesis and investigate the hemo-
static action mechanism and viscoelastic properties of the PU foam. 
We used three different tests in which we compared the PU to collagen and gelatin. The first 
test was performed with human whole blood to analyse the influence of the test materials 
on thrombocyte aggregation and activation. The second test was done with platelet-poor 
plasma (PPP) to analyse the initiation of the coagulation cascade in the absence of suffi-
cient thrombocytes, by the different test materials. The third test was done with a low load 
compression tester (LLCT) to investigate the viscoelastic properties of the test materials both 
under dry and wet conditions. LLCT has been used in earlier studies to measure microbial 
biofilm properties and the viscoelastic properties of human lenses [6,7]. 
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Materials
Tests were performed with PU, Hémocollagène (absorbable collagen hemostat; Septodont, 
Saint-Maur-des-Fossés, France) and Spongostan (absorbable haemostatic gelatin sponge; 
Ethicon, Somerville, NJ, USA).
The tested PU was a block-copolymer composed of urethane hard segments and co-poly-
ether-ester soft segments. The soft segments (total molecular weight: 2.000 g/mol) con-
sisted of 50% DL-lactide and 50% ε-caprolactone. PEG 1.000 was used as initiator for the 
soft segments synthesis, and after that PEG 20.000 was added in a mass ratio of 3 (first PU 
formulation) to 1 (PEG 20.000) to prepare a blend. The urethane segments were synthesized 
with 1,4-butanediisocyanate (BDI) and 1,4-butanediol (BDO). They had a uniform length of 5 
urethane moieties, which resulted in a PU with BDI-BDO-BDI-BDO-BDI urethane segments 
in the polymer. The PU was then dissolved in 1,4-dioxane. After dissolving, the solution was 
poured into a mold and cooled down to −18°C. The solution was freeze-dried at 3 mbar to 
remove the 1,4-dioxane crystals, resulting in an highly porous foam with a porosity of 97% 
and an overall PEG-content of 55 wt%. Overall porosity was calculated after determining the 
weight and dimensions of the foams. The foams had a cylindrical shape with a size of 1 cm3 
and were ultimately sterilized using ethylene oxide. The polymers and foams were manufac-
tured by Polyganics BV (Groningen, the Netherlands).
All materials were processed to cylindrical disks with a diameter of 10 mm and a weight of 
0,01 gram to ensure that the same amount of material was used for each test. For the PU 
this led to a thickness of 2.5 mm. The collagen samples had a thickness of 3.3 mm and the 
gelatin samples had a thickness of 5 mm. From each material, 70 samples were processed 
and tested.
For the analysis of the viscoelastic properties, the original dimensions of the materials were 
preserved. The collagen and gelatin samples had the shape of a cube which measured 1 cm3. 
The PU had a cylindrical form with a diameter and height of 10 mm.
Methods
To analyse the hemostatic action mechanism and viscoelastic properties of the test materi-
als, three different tests were done. For the first test, a thrombocyte count of human whole 
blood was performed after contact with the test materials. For the second test, time to hemo-
stasis in thrombocyte-poor plasma was measured following activation with the test materi-
als. For the third test, a low load compression test (LLCT) was used to analyse the viscoelastic 
properties in wet and dry conditions.
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Thrombocyte count of human whole blood
Blood preparation
The study was approved by the ethics committee of the University Medical Center Groningen, 
the Netherlands. The blood that was used for this study was obtained from six healthy adult 
volunteers. Exclusion criteria were a known disease or use of drugs that could have influence 
on blood coagulation. Each volunteer donated 20 ml of blood which was tested for normal 
thrombocyte count. To prevent the blood from instant clotting, heparin was added to a con-
centration of 1.5 IU of heparin per ml blood. The blood was then divided over 40 eppendorf 
vials, 0.5 ml per vial and kept at room temperature. The tests were finished within two hours 
after the blood was obtained. At the start of each test 0.75 IU of protamine was added to the 
vial with blood to neutralize the effect of heparin.
Test device
An Amelung-coagulometer KC-4 (Lemgo, Germany) was used to rotate the tubes with 0.5 ml 
whole human blood at a constant temperature of 37 °C. After the protamine was added, the 
test materials were placed in the tube with blood during 120 seconds. With the coagulom-
eter four tests could be done simultaneously. In each test round a PU, collagen and gelatin 
sample were tested along with a control without material in a random order. After rotation 
for 120 seconds the materials were removed from the tube with blood. A thrombocyte count 
was then performed with the blood cell analyzer Medonic CA 530 (Medonic, Sweden) to de-
termine the amount of free and thus unaggregated thrombocytes. In 14 of the 140 samples 
the thrombocyte count failed due to an insufficient amount of remaining blood or advanced 
hemostasis of the blood. These samples were excluded from the study.
Coagulation time of thrombocyte poor plasma
Preparation of thrombocyte poor plasma
Five units of citrated human plasma were obtained from the blood bank (Sanquin, Groningen, 
the Netherlands) and pooled. This thrombocyte poor plasma contained less than 30 * 109/L 
Figure 1. Frontal view of the LLCT, 
showing the main components of 
the system.
Linear Positioning stage 
Top plate 
2.5 mm ø 
Load cell 
Bottom plate 
60 x 55 mm 
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thrombocytes (Normal: 150-350 * 109/L). The thrombocyte poor plasma was divided over 
different plastic tubes, 450 µl per tube and kept at room temperature.
Test device
The tubes with thrombocyte poor plasma were placed in the Amelung-coagulometer KC-4 
(Lemgo, Germany) at 37° C and incubated with one of the different test materials during 15 
minutes. Hereafter, the test material was removed from the PPP and 10% v:v of CaCl2 at a 
concentration of 300 mmol was added to neutralize the citrate. Tests were also performed 
with a negative control group without material and a positive control group with a glass tube. 
Due to the negative charge, glass is a strong activator of the contact activation system [8].
The coagulometer was then used to rotate the cups with PPP at a constant temperature of 
37 °C. A metal control ball was placed in the PPP sample. When coagulation of the sample 
led to a higher viscosity the ball was trapped by the fibrin. This was the endpoint of the test 
which was recorded by electromagnetic detection and led to the coagulation time. When the 
endpoint was not reached after 1200 seconds, the test was stopped and excluded from the 
study. This was the case in 10 of the 135 samples. 
Analysis of viscoelastic properties
Test device
The viscoelastic properties of the test materials were analysed with a low load compression 
tester (LLCT). The LLCT consists of a linear positioning stage (Intellistage M-511.5IM; Physik 
instrumente, Karlsruhe, Germany) which is connected to a cylindrical moving upper plate 
with a diameter of 2.5 mm (Figure 1). A bottom stationary plate is fixed to an automatic 
force-compensating balance (SW 50/300, Wipotec, Kaiserslautern, Germany). The load cell 
and linear positioning stage were interfaced to a PC for data acquisition and control using 
LabVIEW 7.1. Movement of the top plate and force registered by the load cell were computer-
stored for further analysis.
Figure 2. Example of a stress re-
laxation curve for PU out of which 
the percentage of stress relaxation 


















Tests were performed both under dry and wet conditions in a random order. The tests under 
wet conditions were done with materials that were submerged in demineralised water for 
200 s. All materials were fully soaked with demineralised water after this time period. The 
mean percentage of demineralised water was 98% in the collagen foam, 90.5% in the gelatin 
foam, and 95.5% in the PU. The test material was placed on the bottom plate and positioned 
under the center of the top plate. The LLCT was then activated and the top plate moved 
downward with a constant speed of 10 µm/s. After the top plate made contact with the foam 
it started compressing it at 0.1%/s till a stress of 90 kPa was reached. The total deformation 
of the material was then recorded at 90 kPa.
Stress-relaxation test
Tests were performed under wet conditions in a random order. The test material was placed 
on the bottom plate and positioned under the center of the top plate. The LLCT was then 
activated and the top plate moved downward with a constant speed of 10 µm/s. When the 
top plate made contact with the foam, it imposed a deformation of 30% in 0.5 s. The load-
ing force which is a parameter for the amount of springback was then monitored for 200 s 
(Figure 2). Out of the loading force the percentage of stress relaxation was calculated.
Statistical analysis
Statistical analysis was performed using SPSS 18.0. Group differences for all tests were cal-
culated by the Mann-Whitney-U-test. P values less than 0.05 were considered statistically 
significant.
Results
Thrombocyte count human whole blood
To analyse the influence of the materials on thrombocyte aggregation and adhesion the 
amount of free thrombocytes in the blood samples was measured after a contact period of 
120 seconds. A low amount of free thrombocytes indicates a high amount of aggregated or 
Table 1. Mean thrombocyte count of the test materials after contact with human whole blood.
Material Number of tests Thrombocytes (x 109/L)
No material 32 213.8 ± 28.8
PU 29 178.0 ± 32.4
Collagen 30 187.2 ± 25.3
Gelatin 35 200.7 ± 31.4
PU, polyurethane.
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adhered thrombocytes. The mean amount of free thrombocytes was calculated and shown 
in table 1. The results are also presented in a boxplot (Figure 3).
The lowest mean amount of thrombocytes was found in the blood samples that had been 
in contact with PU. This was significantly lower than the mean amount of thrombocytes in 
the control group (p < 0.001). The mean amount of thrombocytes in the blood samples that 
had been in contact with collagen was also significantly lower than the mean amount in the 
control group (p < 0.01). Between gelatin and the control group the mean amount of throm-
bocytes was not significant (p = 0.08).
The difference in mean thrombocyte amount was not significant between PU and collagen (p 
= 0.36). The difference between PU and gelatin was significant (p = 0.02), whereas the differ-
ence between collagen and gelatin was not statistically significant (p = 0.07).
Coagulation time pooled plasma
The influence of the test materials on the coagulation cascade was analysed with platelet-
poor pooled plasma. The coagulation time was measured for the different materials. Means 
and standard deviations are noted in table 2 and presented as bar chart in Figure 4.
Figure 3. Schematic representation of the 
amount of thrombocytes for the test mate-
rials after contact with human whole blood. 
For each group, the line in the middle of the 
box represents the median. The lower and 
the upper edges of the box are 1st and 3rd 
quartile, respectively. The fences are drawn 
to the nearest value not exceeding 1.5 (in-
terquartile range) * p < 0.01 compared with 
control group (No material). ** p < 0.001 
compared with control group (No material).  
PU, polyurethane. 
Figure 4. Mean coagulation time of the 
test materials in platelet-poor plasma. 
Mean standard deviations are plotted as er-
ror bars. * p < 0.03 compared with negative 
control group (No material). ** p = 0.001 
compared with negative control group (No 
material). PU, polyurethane. 



























































The mean time to coagulation was the highest for the negative control group in which no 
material was incubated. The mean coagulation time for collagen was significantly lower than 
the negative control group with a p-value < 0.001. The PU also showed a significantly faster 
coagulation than the negative control group (p = 0.03). The coagulation time of gelatin did 
not differ significantly from the negative control group (p = 0.15). The positive control group 
in which the plasma was incubated with glass showed a significantly faster coagulation than 
the negative control group and the other test materials (p < 0.001).
The coagulation time of collagen was significantly lower than PU and gelatin (p < 0.001). 
Between PU and gelatin the difference was not significant (p = 0.13).
Analysis of viscoelastic properties
Stress-strain test
The viscoelastic properties of the test materials were analyzed by performing a stress-strain 
test under dry and wet conditions. Mean deformation under 90 kPa compressive stress from 
12 measurements is presented in a bar chart in figure 5.
The PU foam showed the highest mean deformation under dry conditions. The deformation 
of PU increased when the test was performed under wet conditions (p < 0.001). Collagen 
and gelatin foams showed significantly lower deformation as compared to PU foam in dry 
conditions (p < 0.001). The deformation under wet conditions for collagen and gelatin foams 
increased 4 and 9 times respectively (p < 0.001).
Stress-relaxation test
The springback capability of the materials was analyzed under wet conditions after rapid defor-
mation of 30%. The springback was recorded in terms of percentage stress relaxation and pre-
sented in a boxplot in figure 6. The lower the relaxation, the higher is the springback capability.
The highest percentage of stress relaxation was recorded for the tests that were done with 
gelatin. Collagen gave less relaxation and the lowest percentage of relaxation was seen for 
PU. The differences between the materials were statistically significant (p < 0.001). 
Table 2. Mean coagulation time of the test materials in platelet-poor plasma.
Material Number of tests Coagulation time (s)
No material 14 832.6 ± 248.8
PU 33 676.1 ± 196.4
Collagen 33 496.2 ± 121.1
Gelatin 30 748.6 ± 153.1




In this study, PU showed a significant increase in thrombocyte aggregation and activation of 
the coagulation cascade compared to the negative control group. Collagen showed similar 
results but led to a significantly faster coagulation in the pooled plasma test. This indicates 
that PU and collagen are thrombogenic materials due to their surface reaction with blood 
components. Gelatin did not show any significant differences in thrombocyte aggregation 
and initiation of the coagulation cascade compared to the negative control group. The analy-
sis of the viscoelastic properties showed that the deformation of PU slightly increases under 
wet conditions while the deformation of collagen and gelatin was increased multiple times 
under wet conditions. The stress relaxation was the lowest for PU, followed by collagen and 
gelatin. This indicates that PU has the highest amount of springback after impression under 
wet conditions.
Figure 5. Mean deformation of both 
dry and wet PU, collagen and gelatin 
foams under a compressive stress 
of 90 kPa. Standard deviations of 12 
measurements are plotted as error 
bars, bars with the maximum allowed 
deformation of 90% do not possess any 






































































100 Figure 6. Mean percentage stress 
relaxation in 200 seconds under wet 
conditions for different types of foam 
at 30% deformation. Mean standard 
deviations of 15 measurements are 
plotted as error bars. PU, polyurethane. 
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In the in vivo situation, vessel injury leads to the rapid binding of thrombocytes to the sub-
endothelium [1]. The coagulation cascade is initiated by TF which activates FX after reaction 
with FVII. This leads to fibrin deposition and stabilization of the clot [1]. The initial clot is thus 
formed by thrombocytes and stabilisation of the clot occurs via the coagulation cascade. A 
hemostatic agent should therefore ideally promote both the aggregation of thrombocytes 
and initiation of the coagulation cascade.
In this study both PU and collagen show these characteristics. Collagen is already known as 
an effective hemostatic agent although its mechanism of action is predominantly attributed 
to the promotion of thrombocyte aggregation [3]. This study showed that the hemostatic 
efficacy of collagen also arises out of initiation of the coagulation cascade. An early study by 
Wilner et al. already showed that factor XII can be activated by collagen in thrombocyte poor 
plasma and lead to coagulation via the intrinsic pathway of the coagulation cascade [9]. Al-
though some studies [10-12] questioned the role of factor XII in in vivo clot formation, a study 
by Renné et al. pointed out that the FXII-induced intrinsic coagulation pathway is important 
for clotting in vivo [13]. Other studies also found that factor XII contributes to thrombus for-
mation and activation of the coagulation cascade [14,15].
The fact that PU also leads to increased thrombocyte aggregation and initiation of the coagu-
lation cascade is a confirmation of our hypothesis that the PU provides a surface to which 
thrombocytes can adhere and initiates the coagulation cascade through contact activation.
The results of gelatin fell short compared to collagen and PU in this study. The gelatin showed 
less aggregation of thrombocytes in the human whole blood and longer coagulation time 
with platelet-poor plasma compared to collagen and PU.
A previous in vitro study also showed very low platelet deposition for gelatin when the mate-
rial was exposed to platelet rich plasma [16]. Other studies state that the hemostatic action 
mechanism of gelatin is probably mostly mechanical and seems likely to involve physical 
surface effects rather than any action on the blood clotting mechanism [3,17].
Compression of a wound is known to be effective and important for hemostasis [18]. There-
fore, it is important that a topical hemostatic agent keeps its firmness and shape after it is 
soaked with blood. The results in this study show that the mechanical stability of collagen 
and gelatin foam significantly decrease after getting soaked, whereas PU foam maintained 
its stability. Under dry conditions the PU foam was highly malleable and deformed the most 
easily, whereas collagen and gelatin would require higher forces. Under wet conditions both 
collagen and gelatin foam deformed up to the maximum allowed of 90% and would have 
deformed to much higher values in absence of this limit, indicating that the deformation 
under 90 kPa for PU foam is significantly lower as compared to collagen and gelatin foam. 
In the stress relaxation test the materials were impressed for 30% because surgeons often 
manipulate the hemostatic agent before application to a wound. The 30% was chosen as an 
estimate of the extent to which surgeons generally manipulate the hemostatic agents. The 
tests were performed under wet conditions to mimic the in vivo situation in which the mate-
rials get soaked with blood after application to the wound.
 CHAPTER 5
70
The stress relaxation test showed that PU has the lowest stress relaxation, indicating that 
it has the highest amount of springback and therefore will exert more pressure on a wound 
even after getting soaked with blood. Collagen and gelatin foam on the other hand become 
mushy and formless under wet conditions and therefore might be much less successful in re-
stricting the bleeding. We did not find any indications for possible compressive complications 
due to extreme swelling of gelatin and collagen which is often mentioned in the literature 
[3,19-21]. Furthermore, the stability of PU foam under wet conditions gives it better handling 
capacities than the mushy and formless collagen and gelatin foam. 
The poor viscoelastic properties of gelatin are probably due to the production process in which 
denaturation of collagen leads to breaking of the triple-helix structure [22]. An in vitro study 
by Grover et al. also found that collagen has better viscoelastic properties than gelatin which 
is supported by our stress relaxation results [23]. PU is a synthetic material with attractive vis-
coelastic properties that can be controlled and modified during the production process [24]. 
We found in our study that the viscoelastic properties of PU were only very slightly altered 
under wet conditions. This corresponds to another in vitro study that showed that stress and 
elongation properties changed little when PU containing PEG was hydrated [25].
For the tests on hemostatic action mechanism the materials all had a weight of 0.1 gram. 
We used weight in stead of volume because weight could be more accurately measured. The 
materials had a different density which led to a larger volume of gelatin than the volumes of 
collagen and PU. This could be advantageous for gelatin because the total surface to which 
platelets can adhere was greater than the surfaces of collagen and PU. As gelatin was the 
weakest in both tests this variation has not altered the outcome of this study. 
The analysis of thrombocyte activation was done with human whole blood. The unpredictable 
behaviour of blood in vitro led to early coagulation in some of the samples. Furthermore, in a 
few samples the test material soaked up the majority of blood leaving an insufficient amount 
of blood to accurately perform the thrombocyte count.
Initiation of the coagulation cascade was analysed with thrombocyte poor plasma to mini-
mize the influence of the thrombocyte component on hemostasis. The fact that the PPP 
was not entirely free of thrombocytes could have influenced the test results. In some of the 
samples no coagulation occurred after 1200 seconds. We choose to end the test after 1200 
seconds because no coagulation can be expected after this timeframe.
With the LLCT we were able to accurately analyze and compare the viscoelastic properties of 
the different test materials. The tests under wet conditions were performed with test materi-
als that were soaked with demineralised water instead of blood for practical reasons. This 
could have had a minor effect on the test results but is unlikely to influence differences 
between foams. 
This study showed that the good hemostatic efficacy of PU shown in previous studies is 
predominantly due to its effect on thrombocyte aggregation. The viscoelastic properties of 
the PU ensure good handling capacities and pressure to a wound. Future improvement of this 




This study showed that collagen and PU initiate hemostasis through both thrombocyte ag-
gregation and contact activation of the coagulation cascade. Gelatin did not show improved 
thrombocyte aggregation or initiation of the coagulation cascade compared to the negative 
control group. PU is more firm under wet conditions and shows more springback than col-
lagen and gelatin. We conclude that PU is promising as a topical hemostatic agent because 
it initiates both the coagulation cascade and thrombocyte aggregation and furthermore has 
favorable viscoelastic properties. Future improvement of PU should aim on its capacity to 
initiate hemostasis through contact activation.
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Most topical hemostatic agents that are used during or after surgery are based on animal-
derived products like collagen and gelatin. They carry the potential risk of pathogen transmis-
sion while adjustments in the production process of these materials are limited. A synthetic 
hemostatic agent based on polyurethane (PU) and polyethylene glycol (PEG) was developed 
to overcome these disadvantages. The goal of this study was to compare the degradation 
process of this biomaterial to collagen and gelatin hemostatic agents. Renal functions of the 
animals were determined to analyse the possible nefrotoxicity of PEG.
Samples of the test materials were implanted subcutaneously in both rats and rabbits. The 
animals were sacrificed at certain time intervals up to three years. At these time intervals the 
samples were located and explanted from the animals. Blood was taken from the animals for 
analysis of any abnormalities in urea and creatinine values. After fixation, the samples were 
histologically processed for microscopical evaluation.
The histological examination showed a comparable pattern of degradation for the different 
test materials. However, the degradation process was completed remarkably faster for col-
lagen and gelatin than for PU. Remnants of gelatin and collagen were not seen in the samples 
after 12 weeks and 26 weeks, respectively. For PU, it took up to three years before micro-
particles of the material were no longer detected. All biomaterials showed a good biocompat-
ibility and no severe foreign body reactions occurred. Mean urea and creatinine values stayed 
within the normal range during the three year investigation period.
The good biocompatibility and predictable pattern of resorption indicate that PU can be used 
as a topical hemostatic agent. However, a degradation time comparable to collagen and gela-
tin would be favorable. 
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Introduction
In all surgical disciplines, topical hemostatic agents are used to control local problematic 
bleeding. Most of these hemostatic agents are based on animal-derived products like colla-
gen and gelatin. These materials carry the potential risk of pathogen transmission which can 
result in diseases like Creutzfeld-Jacob or bovine spongiform encephalopathy [1]. A hemo-
static agent made of a synthetic yet biologically friendly material like polyurethane (PU) could 
prevent this risk. Furthermore, the possibility to vary the composition of synthetic biomateri-
als, allows for greater control over material properties and tissue responses.
Biodegradable PU with a total of 55 wt% polyethylene glycol (PEG) has been analysed for its 
hemostatic and mechanical properties in previous studies. The hemostatic efficacy of this ma-
terial has shown to be comparable to topical hemostatic agents like collagen and gelatin [2,3]. 
The viscoelastic properties of PU were favorable compared to collagen and gelatin in an in vitro 
study as PU showed the highest springback capability under wet conditions [4]. Besides hemo-
static and mechanical properties, characteristics like the bioresorption potential, the antigenic-
ity and the tissue reactivity are important for a well balanced, effective hemostatic agent [5].
The goal of this study was to analyse the degradation process and the tissue response of PU 
with 55 wt% PEG and compare this to the degradation process and the tissue response of 
collagen and gelatin hemostatic agents.
The PU is composed of hard segments of 1,4-butanediol and 1,4-butanediisocyanate and 
soft segments of DL-lactide, ε-caprolactone and polyethylene glycol. The good biocompat-
ibility of a comparable PU without PEG has been demonstrated in a previous in vivo study 
[6]. In this study the PU samples were resorbed almost completely after three years. A more 
rapid degradation period would be favorable to prevent the risk of secondary inflammation.
The degradation of PU can be accelerated by combining it with polyethylene oxide (PEO) [7]. 
This is attributed to the hydrophilic nature of PEO, because the presence of a greater volume 
of water within the polyurethane can allow for a greater amount of hydrolysis, and thus deg-
radation, to take place [8,9]. PEO is also known as polyethylene glycol (PEG), depending on its 
molecular weight. In a pilot study in rabbits, a more rapid degradation was observed for PU 
with 23 wt% PEG compared to PU without PEG [10]. In a similar study, PU with 5 wt% PEG 
was tested which resulted in detectable foam remnants after one year [11]. We combined 55 
wt% PEG with PU to further increase the hydrophilicity, and we expect that this material will 
show a more rapid bioresorption than the PU foams with lower percentages of PEG. 
Topical hemostatic agents like collagen and gelatin usually degrade over a time period of 6 
to 12 weeks [12]. The purpose of this study was to analyse the length of degradation of this 
PU foam and compare it to collagen and gelatin hemostatic agents, to determine whether 
the PU foam is suitable for controlling local bleeding during and after surgery. Furthermore, 
the antigenicity and tissue reactivity were evaluated. Renal functions of the animals were 





Implantations were performed with PU, Hémocollagène (absorbable collagen hemostat; 
Septodont, Saint-Maur-des-Fossés, France) and Spongostan (absorbable haemostatic gelatin 
sponge; Ethicon, Somerville, NJ, USA).
The PU was a block-copolymer composed of urethane hard segments and co-polyether-ester 
soft segments. The soft segments (total molecular weight: 2.000 g/mol) consisted of 50% 
DL-lactide and 50% ε-caprolactone. PEG 1.000 was used as initiator for the soft segments 
synthesis, and after that PEG 20.000 was added in a mass ratio of 3 (first PU formulation) to 
1 (PEG 20.000) to prepare a blend. The urethane segments were synthesized with 1,4-bu-
tanediisocyanate (BDI) and 1,4-butanediol (BDO). They had a uniform length of 5 urethane 
moieties, which resulted in a PU with BDI-BDO-BDI-BDO-BDI urethane segments in the poly-
mer. The PU was then dissolved in 1,4-dioxane. After dissolving, the solution was poured 
into a mold and cooled down to −18°C. The solution was freeze-dried at 3 mbar to remove 
the 1,4-dioxane crystals, resulting in an highly porous foam with a porosity of 97% and an 
overall PEG-content of 55 wt%. Overall porosity was calculated after determining the weight 
and dimensions of the foams. The foams used for implantation had a cylindrical shape with a 
diameter of 10 mm, a thickness of 1 mm and an average weight of 5 mg. The polymers and 
foams were manufactured and supplied by Polyganics BV (Groningen, the Netherlands), and 
were sterilized using the ethylene oxide process.
The collagen and gelatin foams were also processed to cylindrical discs with a diameter of 10 
mm and an average weight of 5 mg to ensure that the same amount of material was inserted. 
The collagen samples had a thickness of 1,5 mm while the gelatin samples had a thickness 
of 2,5 mm. For traceability, a nondegradable polyamide suture (Ethilon®, 4-0, Ethicon) was 
attached to the discs as a reference.
Animals
Six-week-old male Wistar rats (n = 36) were used at time intervals up to 1.5 years (Table 
1). In each rat six discs were implanted, in subcutaneous pockets, parallel to the spine in 
two rows of three. Half of the rats (n = 18) received six PU discs and the other half (n = 18) 
received two discs of each material (PU, collagen, gelatin). The position of the implants was 
rotated to exclude influences of the site of implantation. At each time interval four rats were 
terminated, two rats with only PU and two rats with PU, collagen and gelatin. We used eight 
time intervals up to 1.5 years for which we needed 32 rats. Four extra rats were implanted 
that served as back-ups in case of adversities. At 61 weeks one of the rats was terminated 
because of severe weight loss. The implants from this rat were not histologically analyzed. As 
no other adversities occurred, the three remaining back-up rats were terminated at the latest 
time interval for the rats at 1.5 years. 
New Zealand White rabbits (n = 15) were used for the extended time intervals, because of 
their longer life span (Table 1). The animals were three months of age at the time of implanta-
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tion. In each rabbit eight discs were implanted subcutaneously in two rows of four. Five rab-
bits received eight PU discs while the other ten rabbits were implanted with a combination 
of four PU discs, two collagen discs, and two gelatin discs. Similar to the rats, the position of 
the implants was also rotated in the rabbits. At the time intervals of 1 and 1.5 year, 2 rabbits 
were terminated and 4 and 7 rats, respectively. These two overlap time intervals were chosen 
to compare the tissue response and degradation of the materials between rats and rabbits.
In accordance to the rat series, two of the fifteen rabbits were implanted and served as back-
ups in case of adversities. As no adversities occurred, the choice was made to terminate an 
extra rabbit at the 2.5 and 3 year time interval.
The rats and rabbits were obtained from Harlan Laboratories BV, the Netherlands. All animals 
were housed according to the Dutch national code of practice for animal welfare and had un-
limited access to standard food and water. The experiment was approved by the Committee 
for Animal Experiments, University of Groningen, the Netherlands.
Methods
Subcutaneous implantation
All animals were weighed before implantation. The rats were anaesthesized with 2% isoflurane. 
Anesthesia for the rabbits was induced by intravenous administration of 1.0 mL pentobarbital 
(6%) and maintained with 2–3% isoflurane. The dorsal skin of the animals was shaved as to 
implement subcutaneous pockets parallel to the spine. The discs were placed in these pockets 
and closed with a suture. All wounds were inspected daily during the first week postoperatively. 
At the designated time intervals the animals were again weighed and anesthesia was induced. 
Venous blood was collected for analysis of the renal functions which was determined by 
measuring the blood urea nitrogen (BUN) and the creatinine concentration with a portable 
clinical analyzer (i-STAT 1 Analyzer; Abbott Laboratories, Abbott Park, IL, USA). The kidneys 
were then removed from the animal which caused death by bleeding. Kidney samples were 
taken and stored in either 4% phosphate buffered paraformaldehyde (PFA) or liquid nitrogen 
to be available for possible future analysis.
The explantation procedure for the samples was the same for rats and rabbits. The dorsal skin 
was shaved and cut open along the length of the spine. Implant sites were located using the 
blue polypropylene suture that served as implant reference. After macroscopical inspection 
the implants or the remains of, were explanted, including the overlaying skin. In some cases 
the suture could not be found and no indication of the biomaterial was seen. Therefore, the 
number of evaluated samples per time interval was not always equal. In table 2 and 3 the 
number of samples that could be evaluated per time interval is noted. The samples were fix-
ated in 4% phosphate buffered PFA and subsequently embedded in GMA. Tissue blocks were 
cut perpendicular to the implant with a thickness of 2 µm and the sections were stained with 
Toluidin Blue or Toluidin Blue/Basic Fuchsin. Care was taken to orient the blocks precisely in 
order to determine the breakdown of the implants accurately.
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Light microscopic evaluation of the samples was done using a semiquantitative scoring 
method (Table 2 and 3). All samples were observed and discussed by two investigators.
Statistical analysis
Statistical analysis was performed using SPSS 20.0. The Kruskal-Wallis test was used to com-
pare the number of cell layers in the fibrous capsule between the materials. A p value less 
than 0.05 was considered statistically significant.
Results
Post-operative inspection of the animals revealed no inflammation around the implantation 
sites or impaired healing of the wounds at any time interval. The results of the histological 
examination were scored in a similar way as a previous study on the degradation of PU with-
out PEG to facilitate comparison between the studies [6]. Table 2 and 3 present an overview 
of the histological examination and the rate of degradation is presented in Figure 1.
The histological examination showed a comparable pattern of degradation for the different 
test materials. The pattern of degradation could be divided in three different stages. These 
stages are encapsulation/infiltration, degradation/fragmentation, and resorption. The time 
to complete resorption was less for collagen and gelatin than for PU. The collagen and gelatin 
implants showed a similar degradation time until 12 weeks. From 26 weeks on, the degrada-
tion of gelatin progressed more rapid than the degradation of collagen.
The encapsulation/infiltration stage was seen in the collagen and gelatin implants during the 
first 2 weeks and in the PU implants as long as 12 weeks (Figure 2). The characterization of 
encapsulation of the biomaterial at this stage predominantly consisted of various numbers of 
fibroblast layers. These fibroblast layers would maintain their infiltration and encapsulation 
capabilities to smaller fragments of biomaterials as degradation sets in. Phagocytic activ-
ity by macrophages was seen in all biomaterials after 1 week. However, the concentration 
of macrophages was higher in the collagen and gelatin than in the PU foam. After 4 weeks 
the number of macrophages in the PU implants increased. These macrophages showed an 
increase in phagocytic activity after 12 weeks. A small number of acute inflammatory cells 
and foreign body giant cells (FBGCs) were seen around the biomaterials at the time intervals 
from 4 to 26 weeks. The fibroblastic cell layers around the biomaterials reached an average 
thickness of 4-6 cell layers. In table 2 the amount of cell layers at each time interval is pre-
sented for all biomaterials. The fibrous capsule was present around the collagen and gelatin 
materials during the first 2 weeks and around the PU implants up to 12 weeks. The difference 
in the amount of cell layers during week 1 (p=0.91) and week 2 (p=0.83) was not significant 
for the different biomaterials. 
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Figure 1. Overview of the level of degradation for the three biomaterials over time. 0: signs of degradation 
at the border of the material. 1: degradation in ½ of the material. 2: degradation in the centre of the mate-
rial. 3: with partly loss of porous structure. 4: intracellular remnants of material. 5: signs of cellular activity 






















Table 1. Overview of the terminated animals per time interval and their mean weight, BUN and 
creatinine at the time of sacrifice. BUN, blood urea nitrogen; SD, standard deviation.
Time interval Mean weight with SD 
(grams)
Mean BUN with SD 
(mmol/L)
Mean creatinine with 
SD (µmol/L)
1 week (4 rats) 284.8 (± 6.8) 6.9 (± 0.42) 25.8 (± 4.9)
2 weeks (4 rats) 328.3 (± 25.7) 6.3 (± 1.09) 23.3 (± 4.1)
4 weeks (4 rats) 356.3 (± 34.5) 7.1 (± 0.39) 22.3 (± 3.8)
12 weeks (4 rats) 446.3 (± 43.2) 6.4 (± 0.26) 23.5 (± 3.4)
26 weeks (4 rats) 558.0 (± 45.6) 5.6 (± 0.32) 28.0 (± 4.2)
39 weeks (4 rats) 591.5 (± 51.5) 6.7 (± 0.60) 23.0 (± 4.2)
1 year (4 rats) 658.0 (± 34.2) 7.9 (± 0.50) 32.5 (± 7.0)
1 year (2 rabbits) 2900 (± 0) 5.1 (± 0.28) 101.5 (± 9.2)
1.5 years (7 rats) 584.9 (± 43.8) 9.3 (± 0.50) 41.9 (± 10.6)
1.5 years (2 rabbits) 3150 (± 353) 7.9 (± 1.1) 101.0 (± 7.1)
2 years (3 rabbits) 3333 (± 416) 7.2 (± 1.3) 92.3 (± 5.5)
2.5 years (4 rabbits) 3250 (± 191) 8.1 (± 0.5) 113.5 (± 22.8)
3 years (4 rabbits) 3600 (± 337) 5.9 (± 0.6) 107.0 (± 18.1)
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Figure 2. LM micrograph (10x) of a gelatin (G) sample and a PU sample after 1 week. A: Around the gelatin 
sample a capsule (C) is formed and the ingrowth of fibrous tissue (F) has started. B: A capsule (C) has also 
formed around the PU sample after 1 week but ingrowth is less clearly compared to gelatin. Also note the 
high density of PU compared to gelatin. PU, polyurethane foam.
Figure 3. Overview of a gelatin (G) sample after 4 weeks. Figure 3A shows an overview (2.5x) of the gelatin 
sample after 4 weeks. Note the complete ingrowth of fibrous tissue (F) in the gelatin sample. Figure 3B (10x) 
shows a detail of the infiltrated gelatin sample. The disintegration of the biomaterial marks the start of the 





Figure 4. Overview of a PU sample after 39 weeks (A: 2.5x and B: 10x). Note the degradation and frag-
mentation of the biomaterial which is similar to the degradation stage of gelatin after 4 weeks. Ingrowth of 




The degradation/fragmentation stage began in the collagen and gelatin implants after 4 weeks 
while this commenced after 26 weeks with regards to the PU foam. The initial fibrous encap-
sulation was followed by a continuous ingrowth of fibrous tissue as a result of the continuous 
degradation and fragmentation process of the biomaterial. Early in this process vascularisa-
tion was observed, often near new fibrous tissue and in the vicinity of advanced degraded 
biomaterial. Major ingrowth of fibrous tissue in gelatin, seen at 4 weeks (Figure 3) corre-
sponds to the ingrowth in PU foam after 26 to 39 weeks (Figure 4). 
During this stage the macrophages showed the most phagocytic activity. As the resorption 
reached its final stage, the number of macrophages and their activity would also gradually 
decrease.
The resorption stage started after 12 weeks for the collagen and gelatin implants while resorp-
tion of the PU implants was seen after one year. The majority of fragmented particles of col-
lagen and gelatin were phagocytosed by the macrophages at the 12 week interval. After 26 
B
Figure 5. Detail (A: 20x and B: 40x) of the intracellular appearance of PU after 1.5 years in a rat. Note the 
nucleoli (N) of the macrophages that contain remnants of the biomaterial. PU, polyurethane foam.
A
Figure 6. The intracellular configuration of PU after 2 years in a rabbit. Figure 6A (40x) shows the arrange-
ment of macrophages containing PU near a blood vessel (B). Further magnification (100x) in figure 6B shows 














































































































































































































































































































































































































































































































































































































































































































































































































weeks, intracellular remnants of collagen were still visible. Gelatin showed no biodegradable 
products after 26 weeks although there were some areas with increased phagocytic activity 
indicative for the presence of biomaterial. After 39 weeks, no signs of cellular activity in-
dicative of degradation were seen in the gelatin samples. The collagen implants at 39 weeks 
showed increased cellular activity indicative for the presence of biomaterial. Beyond one year, 
no signs of cellular activity indicating degradation were seen in the collagen samples. 
The phagocytosis of PU particles that was first seen at the one year time interval was still 
visible after 2.5 years. At the longest time interval of 3 years, PU implants showed areas 
with phagocytic activity without visible remnants of biomaterial. Although the PU was not 
detectible in these samples, the presence of macrophages is indicative for the presence of 
biomaterial. Thus, the PU definitely shows a slower degradation than gelatin and collagen. 
The degradation of PU had progressed further in the rabbits than in the rats at the 1 year 
interval. Fragmented pieces of PU were seen in some of the rats after 1 year, whereas in the 
Legend table 2 and 3
Fibrous capsule 
 Number of cell layers
Tissue ingrowth
0. No ingrowth
1. Ingrowth in ¼ of the material
2. Ingrowth in ½ of the material
3. Ingrowth in ¾ of the material
4. Infiltration of tissue into the whole area of the foam
–. Disappearance of foam structure
Macrophages/foreign body giant cells (FBGCs)/ cells with phagocytic activity (WFA)
0. Hardly any cell present
1. Low number of cells
2. Low to medium number of cells
3. Medium number of cells
4. High number of cells
Light Microscopy (LM) degradation
0. Signs of degradation at the border of the material
1. Degradation in ½ of the material
2. Degradation in the centre of the material
3. With partly loss of porous structure
4. Intracellular remnants of material
5. Signs of cellular activity indicative of degradation without visible material
6. No signs of cellular activity indicative of degradation
Stage of tissue response and degradation
 Encapsulation and infiltration (E/I)
 Degradation and fragmentation (D/F)
 Resorption (R)
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rabbits only intracellular remnants of PU were detectible at this same time interval. At 1.5 
years intracellular remnants of PU were seen in both rats and rabbits. This was characterized 
histologically by macrophages that phagocytised PU particles (Figure 5 and 6).
   
Renal functions
Renal functions of the animals were determined by measuring the blood urea nitrogen (BUN) 
and the creatinine concentration when the animals were sacrificed. These analyses were to 
determine whether implantation of small amounts of PEG would lead to deterioration of the 
renal function. Table 1 presents an overview of the mean concentrations of urea and creati-
nine per time interval. The mean weight at the time of sacrifice and the number of animals 
per time interval is also noted. In the rats a total of 0.006 or 0.017 grams of PEG was im-
planted, for the rabbits this was 0.011 or 0.022 grams. The amount was dependant on the 
implantation of the three different test materials in the animals or solely PU. 
The normal blood values for BUN and creatinine in Wistar rats are 2.9–9.8 mmol/L and 35–
332 µmol/L respectively [14]. The urea levels of all rats stayed within the normal range except 
for one of the rats after 1.5 years who slightly exceeded the maximum value (9.9 mmol/L). The 
values for creatinine stayed within or below the normal range. In New Zealand White rabbits 
the normal blood values for BUN are 2.9–8.9 mmol/L and the normal blood values for creati-
nine are 12–147 µmol/L [15]. These values were not exceeded in any of the rabbits.
Discussion
This implantation study was undertaken to examine the tissue-response and to compare 
the degradation processes and degradation time of PU foam to commonly used hemostatic 
agents like collagen and gelatin. To acquire a more rapid degradation process a high percent-
age of PEG was introduced in the composition of the PU foam. We found that the degrada-
tion time of PU did not match that of gelatin and collagen. It took 3 years before particles 
of PU implants were no longer detected. Gelatin and collagen particles were not seen after 
respectively 26 weeks and 39 weeks. This showed that the degradation process of the PU 
implant lagged considerably compared to collagen and gelatin. Furthermore, the degradation 
of gelatin seems to go somewhat faster than the degradation of collagen. 
All three biomaterials followed a corresponding degradation pattern of encapsulation/infil-
tration, degradation/fragmentation and ultimately resorption. Therefore, a comparison be-
tween the three biomaterials could be made.
In the in vivo study by Van Minnen et al. [6] macrophages containing phagocytosed PU were 
found after 3 years of implantation. The porous structure of PU without PEG was mostly in-
tact after 26 weeks, and this structure only started to disappear from 39 weeks onward [6]. 
In comparison to this study, minor differences in degradation time were noticed. In our study, 
macrophages containing phagocytosed biomaterial were not found after 3 years but were 
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seen up to 2.5 years. Also, the porous structure of PU with 55 wt% PEG started to disappear 
from 26 weeks onward. Therefore, it seems that the degradation of the current PU with 55 
wt% of PEG occurs more rapidly than the degradation of PU without PEG. This small difference 
could be attributed to the PEG as this increases hydrophilicity and thus increases initial degra-
dation rate [8,9]. The complete degradation of the remaining PU moieties by macrophages did 
not progress substantially faster as the process still took up to 2.5 years. Another difference in 
our study compared to the study by Van Minnen et al. [6] is that we introduced an extra deg-
radation level in which signs of cellular activity indicative of degradation were seen, without 
visible material. This level indicates that some biomaterial particles might still be present but 
are too small to be detected with light microscopy. This level of degradation was seen in the 
PU samples after 3 years. We estimate that it might take up to 3.5 or 4 years before signs of 
degradation are not longer detectable anymore in areas where PU was implanted. 
An in vitro study by Fromstein et al. showed a rapid initial degradation of PU with a mass per-
centage of 50% of polyethylene oxide (PEO), followed by prolonged degradation in the later 
stages [9]. This corresponds to our results as we used a comparable percentage of the nearly 
identical polyethylene glycol (PEG) in our PU foam.
Earlier studies have described the degradation period of gelatin and collagen to vary from 4-6 
weeks and 6-12 weeks respectively [12,16]. The degradation of these materials is primarily 
accounted for by enzymes, such as gelatinase, collagenase and telopeptide cleaving enzymes 
[17,18]. In our study, intracellular remnants of gelatin were seen up to 12 weeks after im-
plantation whereas collagen was traceable up to 26 weeks after implantation. We do not 
have a clear explanation for this difference but it could be contributed to the relatively small 
animals that were used in our study. The enzymatic activity in these smaller animals might 
be lower than in larger animals. We already assessed that the degradation process progressed 
faster in the rabbits than in the rats. Earlier studies were done with larger subjects like dogs, 
pigs and humans [19-21]. 
The degradation duration of PU in humans may therefore possibly be less than 2.5 years. 
A comparable study by Alpaslan et al. in which gelatin and collagen were subcutaneously 
implanted in rats showed that the materials had decreased in size and were surrounded 
with fibrous tissue 45 days after implantation [22]. In our study the degradation seemed to 
have progressed somewhat faster after 4 weeks as the material definitely showed signs of 
fragmentation.   
Other studies investigated the properties and possibilities to increase the degradation rate 
of PU for applications as neural conduits or bone replacements [23,24]. This showed that 
alteration of the molecular structure of PU could influence the rate of hydrolysis, which plays 
a major role in biodegradable polymers [25]. These alterations focused on the soft segments 
like PEO which increases hydrophilicity and hygroscopy of PU, thus initiating degradation. 
However, when PU is combined with high amounts of PEO the material becomes weak and 
tacky [26]. Our PU foam was combined with the maximum concentration of 55 wt% PEG 
which is similar to PEO. A higher percentage of PEG would lead to insufficient mechanical 
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properties. However, this modified PU foam with a high percentage of PEG did not result in 
the desired duration period of degradation similar to gelatin and collagen. The material did 
show an earlier disintegration compared to PU without PEG [6]. The time to complete degra-
dation however, still took up to 2.5 years. A faster PU resorption would be favorable because 
the material could lead to secondary inflammation while its presence as a hemostatic agent 
is no longer necessary. A possibility to further increase the rate of degradation could be found 
in the alteration of the hard segments. This has been done by Skarja et al. who specifically 
designed enzyme sensitive linkages in the hard segment of the PU [26,27].
The biocompatibility of PU with 55 wt% PEG has shown no severe inflammatory or foreign 
body response during the complete process of degradation. This is in accordance with other 
studies that analysed the biocompatibility of PU [6,25].
The possible toxicity of PEG was also examined in this study. To measure toxicity, blood sam-
ples were taken prior to termination for analysis of renal parameters blood urea nitrogen 
(BUN) and creatinine. These values stayed below or within the normal range. However, after 
1.5 years the BUN values in rats increased near the maximum normal value. One of the rats 
even slightly exceeded this value. An increase of these parameters towards the maximum 
normal value has been described earlier in healthy rats as the age increases [28]. Based on 
these results, it is not expected that the implantation of PU with 55 wt% PEG will lead to 
nefrotoxicity in humans. Furthermore, the relative amount of PEG in humans would be con-
siderably lower than the amount of PEG we implanted in rats and rabbits. An explanation for 
the relatively low creatinine levels in rats may be the lack of exercise.
In this degradation study we chose to implant the biomaterials in animals because this would 
provide us with the most data and reliable in vivo information. The materials were implanted 
in both rats and rabbits as the life span of rats would not exceed the three year term, chosen 
for this study. Implantation of the biomaterials in rabbits only, was not practicable for logistic 
and financial reasons. Although the rate of degradation was a little faster in rabbits, the over-
all process of degradation could be followed accurately. 
The choice, to sacrifice rats with several successive short term time intervals at the beginning 
of the study, was made to follow the degradation process of the rapid degrading abilities of 
gelatin and collagen more accurately [22]. 
The rapidly changing stages of degradation of collagen and gelatin after only 2 weeks justify 
the choice of short term time intervals. The PU implants also showed a change in degrada-
tion after 1 and 2 weeks. This change in different levels of degradation could indicate that the 
initial degradation was induced by the high percentage of PEG.  
A semiquantitative scoring method was needed to obtain an overall representation of the 
degradation processes of all biomaterials in time. At the later time intervals, relocating the 
biomaterial became more difficult. The explanted tissue might therefore not also have been 
the center of the degradation area. Due to the large number of implants and the gradual 
pattern of degradation we still could acquire a reliable impression of biodegradation of PU, 
collagen and gelatin. 
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Conclusions
The degradation process of PU, collagen and gelatin follows a gradual and comparable pat-
tern towards resorption. However, the time to complete resorption is considerably faster for 
collagen and gelatin than for PU. The biocompatibility of all biomaterials was amply sufficient 
and no inflammatory reaction or severe foreign body response occurred. The biocompatibility 
and predictability of degradation indicate that PU can be used as a topical hemostatic agent 
but a more rapid degradation would be favorable. Future research should therefore aim on 
PU foam with the desired degradation rate of the polyurethane moieties yet maintaining its 
hemostatic and viscoelastic properties.
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Risk of bleeding after dentoalveolar surgery in 
patients taking anticoagulants








To avoid increasing the risk for thromboembolic events, it is recommended that treatment 
with anticoagulants should be continued during dentoalveolar operations. We evaluated the 
incidence of bleeding after dentoalveolar operations in a prospective study of 206 patients, 
103 who were, and 103 who were not, taking anticoagulants. Seventy-one were taking 
thrombocyte aggregation inhibitors (TAIs) and 32 with vitamin K antagonists (VKAs). Patients 
were treated according to guidelines developed at the Academic Centre for Dentistry Am-
sterdam (ACTA), the Netherlands. The patients underwent surgical extraction, non-surgical 
extraction, apicectomy, or placement of implants. They received standard postoperative care 
and patients taking VKAs used tranexamic acid mouthwash postoperatively.
No patient experienced severe bleeding requiring medical intervention. Seven patients (7%) 
on anticoagulant therapy suffered mild post-operative bleeding. Patients taking VKAs report-
ed three mild bleeding incidents (9) compared with 4 (6%) in the group taking TAIs. Among 
patients without anticoagulant therapy, two (2%) suffered mild bleeding. The between-group 
differences were not significant. All bleeding incidents were controlled by the patients them-
selves with compression with gauze.
We conclude that dentoalveolar surgery is safe in patients being treated with anticoagulants 




Oral anticoagulant therapy is common and has been proved to be effective in preventing 
thromboembolic events [1,2]. The most commonly used agents are thrombocyte aggrega-
tion inhibitors (TAIs; like acetylsalicylic acid and clopidogrel) and vitamin K antagonists (VKAs; 
like warfarin, acenocoumarol, and fenprocoumon). 
As patients increasingly tend to keep their natural dentition up to higher ages, dentoalveolar 
surgery is more frequently indicated for elderly people using anticoagulant therapy. Some 
health care providers still instruct all patients to discontinue anticoagulant therapy before 
dentoalveolar surgery, regardless of the individual thromboembolic risks of the patient. How-
ever, this can result in thromboembolic events (such as deep vein thrombosis and pulmonary 
embolism) that are worse than postoperative bleeding after dentoalveolar surgery [3].
The Academic Centre for Dentistry Amsterdam (ACTA) of the Netherlands developed guide-
lines based on the publications of van Diermen et al. [4-6]. These guidelines recommend 
that anticoagulants should be continued during dentoalveolar surgery under well-described 
conditions [7]. These guidelines are accepted by the professional organization for dentists in 
the Netherlands (NMT) and the organizations charged with ambulant antithrombotic treat-
ment, and are used by most Dutch oral health care professionals.
The guidelines make a distinction between the two types of anticoagulants. For both TAIs and 
VKAs accounts that the dentoalveolar surgery should involve no more than three extractions 
at the same time, surgical removal of wisdom teeth, periodontal treatment, apicectomies, 
abscess incision, or the placement of a maximum of three implants. Patients using one TAI 
can continue this agent during dentoalveolar surgery without further restrictions. In contrast, 
patients on VKAs can continue these agents only when a number of specific conditions are 
met. The international normalized ratio (INR), measured within 24–72 hours preoperatively, 
must be ≤3.5. Furthermore, the operation must be performed as atraumatically as possible, 
the wound must be sutured after extraction, and the patient should leave the hospital with 
adequate instructions only once the bleeding has stopped. Finally, the patient should rinse 
with tranexamic acid 5% for five days postoperatively [7].
In the present study we evaluated the ACTA guidelines to find out whether these procedures 
led to increased postoperative bleeding. We compared the incidence of postoperative bleed-




The study group comprised 206 patients who were referred to the Department of Oral and 
Maxillofacial Surgery of the University Medical Center Groningen, the Netherlands, for a type 
of dentoalveolar surgery meeting the ACTA guidelines, i.e., with a maximum of three extrac-
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tions, apicectomies, or implant placements performed at the same time. The types of dento-
alveolar surgery required were divided into four categories: surgical extractions, non-surgical 
extractions, apicectomies, and implant placement. Extractions were defined as surgical when 
the surgeon had to incise the gingiva before extraction.
Of the 206 included patients, 103 used oral anticoagulant therapy (therapy group) and 103 
did not use any anticoagulant therapy (control group). Patients on VKAs were included if their 
INR, measured within 72 hours prior to surgery, was in the range from 1.8–3.5. Patients on 
TAIs were included if they used only one TAI.
Exclusion criteria were inherited or acquired coagulopathy from systemic. Additionally, pa-
tients in the control group were excluded if they used any coagulation-altering medication. 
The study was conducted according to the Declaration of Helsinki, and informed consent was 
obtained from all participants. 
Study protocol
In this prospective study, patients were treated according to the ACTA guidelines. Before the 
procedure, all patients received a local anesthetic (4% articaine with 1:100,000 epineph-
rine). The operation was performed as atraumatically as possible and the wound was sutured 
after surgery. After extraction, patients were instructed orally and in writing to apply gauze 
compression for 30 minutes immediately after the operation. Patients were not allowed to 
leave the hospital before the bleeding had stopped, and were instructed to call the depart-
ment of oral and maxillofacial surgery if the bleeding did not stop after 30 minutes. The 32 
patients who used VKAs were instructed to rinse with 5% tranexamic acid four times a day 
for five days postoperatively.











Mean age in years at time 
of treatment (range)
62 (23-86) 56 (21-85) 59 (21-86)
Surgical extractions 
(mild bleeding)
48 (5) 55 (1) 103 (6)
Non-surgical extractions 
(mild bleeding)
42 (2) 37 (1) 79 (3)
Apicectomies 
(mild bleeding)
5 (0) 4 (0) 9 (0)
Implant placement
(mild bleeding)
8 (0) 7 (0) 15 (0)
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Two types of postoperative bleeding were defined. If the patient came to the hospital because 
the bleeding could not be stopped at home, it was scored as severe. At one week postopera-
tively, all included patients were called by a researcher to ask if postoperative bleeding had 
occurred that was stopped at home by compression with gauze; such bleeding was scored 
as mild.
Statistical analysis
Data were analysed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as 
mean and standard deviation (SD). Continuous variables were assessed using the Student’s 
t-test, and dichotomous variables using the Pearson’s chi-squared or Fisher’s exact test, as 
appropriate. Linear regression analysis was used to determine the relationship between INR 
value and mild bleeding incidents. A p value of <0.05 was considered statistically significant. 
Results
Of the total 206 included patients, 143 were male and 63 were female, and the mean age 
was 59 years (range, 21–86 years) at the time of treatment. Table 1 summarizes the patient 
characteristics and the types of surgery that were performed. 
The difference between the sexes was not significant (p=0.29), while the difference in mean 
age at the time of treatment was (p<0.01). The most frequently performed procedures were 
surgical and non-surgical extractions, and all bleeding incidents occurred in patients who 
underwent these procedures. No postoperative bleeding incidents were recorded in patients 
who underwent apicectomies or implant placements.
Bleeding incidents were most common in patients who underwent a surgical extraction 
while they were on anticoagulant therapy. However, this incidence was not significantly dif-
ferent from that in patients who underwent non-surgical extractions while on anticoagulant 
therapy (p=0.4). Among patients who did not use anticoagulant therapy, the groups that 
underwent surgical extractions and non-surgical extractions each reported one postoperative 
bleeding incident. Although the non-surgical group was smaller, the between-group differ-
ence in incidence was not significant (p=1.0). 
Table 2. Number (%) of incidents of postoperative bleeding.
None (n=197) Mild bleeding (n=9)
Anticoagulant (n=103) 96 (93%) 7 (7%)
No anticoagulant (n=103) 101 (98%) 2 (2%)
There were no episodes of severe bleeding.
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Regarding the major groups of patients with and without anticoagulant treatment, table 2 
presents the number of postoperative bleeding incidents per group.
None of the included patients experienced severe postoperative bleeding. Patients without 
anticoagulant therapy experienced a lower number of mild bleeding incidents than the group 
with anticoagulant treatment; however, the difference between these groups was not signifi-
cant (p=0.17). 
Table 3 shows the data according to the different types of anticoagulant therapy. The group of 
patients that used VKAs had the highest percentage of mild postoperative bleeding incidents, 
and had a mean (range) INR of 2.6 (1.9–3.4). The 3 patients that suffered from a mild bleed-
ing incident had an INR of 2.0, 2.9 and 3.0. Linear regression analysis revealed that the INR 
value was not correlated with the occurrence of mild bleeding incidents (β=0.41, SE=0.28, 
p=0.14). Patients using VKAs had a non-significantly higher incidence of mild postopera-
tive bleeding compared to patients that used TAIs (p=0.67) and patients who did not use 
anticoagulants (p=0.09). Patients using no anticoagulant therapy had the lowest incidence 
of bleeding, but the difference between this group and the patients that used TAIs was also 
not significant (p=0.23). Figure 1 presents an overview of the percentages of mild bleeding 
incidents in the different groups.
Discussion
Continuation of anticoagulant therapy can be extremely important for patients with a high 
thromboembolic risk, such as patients with mechanical heart valve prostheses and recurrent 
or recent thromboembolic events. When planning dentoalveolar surgery in such patients, the 
possible consequences of postoperative bleeding in patients on continuous anticoagulant 
therapy must be weighed against the possible consequences of a thromboembolic event. 
To help guide such decisions, here we analysed the frequency and severity of postoperative 
bleeding after dentoalveolar surgery in patients with and without anticoagulant therapy.
None of the patients in our study exhibited severe postoperative bleeding. This is in accor-
dance with the results of Napenas et al., who found no postoperative bleeding complications 
Table 3. Number (%) of mild postoperative bleeding incidents by type of anticoagulant.
No bleeding Mild bleeding
Thrombocyte aggregation inhibitors (n=71) 67 (94%) 4 (6%)
Vitamin K antagonists (n=32) 29 (90%) 3 (9%)
No anticoagulant treatment (n=103) 101 (98%) 2 (2%)
There were no episodes of severe bleeding.
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that resulted in visits or phone calls among 43 patients receiving single or dual antiplatelet 
therapy; however, that study did not follow-up with patients after surgery to record mild 
postoperative bleeding incidents [8].
In our study, we called the patients one week after surgery and found that 6.8% of the pa-
tients on anticoagulant therapy suffered from a mild postoperative bleeding. In a similar 
study by Brennan et al., patients using one TAI were called two days after dentoalveolar sur-
gery; of 14 patients, 2 (14%) reported bleeding that stopped after applying gauze compres-
sion at home [9]. This difference in incidence might be explained by the relatively low number 
of patients in the latter study, as one postoperative bleeding incident leads to a considerable 
percentage fluctuation. 
Other studies evaluating the safety of continuing of anticoagulant therapy during dentoal-
veolar surgery have recorded prolonged bleeding time or the severity of intraoperative bleed-
ing. Lillis et al. reported prolonged immediate bleeding after extraction in 2 out of 78 patients 
(2.6%) taking one TAI, and in 2 out of 532 patients (0.4%) without anticoagulant therapy; 
this difference was not statistically significant [10]. In accordance with our study, they re-
ported no late bleeding complications among their patients. Ardekian et al. examined the 
severity of intraoperative bleeding during dentoalveolar surgery [11]. Among the 19 patients 
that used one TAI, 4 (21%) experienced severe intraoperative bleeding, which was a signifi-
cantly higher incidence than that found in patients using no anticoagulant therapy (10%). All 
bleeding could be controlled by suturing the wound and applying pressure with gauze, and no 
uncontrolled postoperative bleeding was reported during the week after surgery. 
In the present study, we chose to record the frequency and severity of postoperative bleeding 
after dentoalveolar surgery because we feel that this is the most clinically relevant parameter. 
Unlike most studies that have analysed the safety of continuing anticoagulant therapy during 
dentoalveolar surgery, we contacted all patients one week postoperatively to record whether 
bleeding had occurred at home. This method enabled us to also analyse the mild bleeding in-
Figure 1. Percentage of mild postoperative bleeding incidents for the different groups. ACT, anticoagulant 





















































cidents, and any severe bleeding incidents that might have been treated by another hospital, 
which would go unnoticed in studies that only record whether a patient seeks contact after 
dentoalveolar surgery.
For the therapy group in this study, we included all patients who met the conditions de-
scribed in the ACTA guidelines. Because these guidelines address both the use of TAIs and 
VKAs, our population included patients that used either of these therapies. This enabled us 
to compare the percentage of postoperative bleeding according to the different anticoagulant 
therapies. We found that the VKAs led to a higher percentage of mild bleedings, although this 
difference was not significant. However, any comparison between these treatment groups 
should be interpreted cautiously; TAIs are prescribed more often, and thus the study included 
a higher amount of patients that used this type of medication.
The ACTA guidelines were modified in 2013, and now state that dual TAI therapy can also be 
continued during dentoalveolar surgery. As the subjects in our study were recruited before 
2013, patients on dual TAI therapy were not included. 
According to the ACTA guidelines, the antifibrinolytic agent tranexamic acid is indicated in 
patients that use VKAs. Patients that used a TAI or who did not use anticoagulant medica-
tions did not receive treatment with tranexamic acid or other topical hemostatic agents. This 
was in accordance with other studies that have only used topical hemostatic agents in cases 
of postoperative bleeding or prolonged bleeding time [10,12]. However, there is no available 
evidence-based protocol for determining when topical hemostatic agents are indicated dur-
ing or after dentoalveolar surgery.
The composition of the presently studied population could have influenced the results in 
several ways. All mild postoperative bleeding incidents occurred in patients who underwent 
surgical or non-surgical extractions, while none were seen in patients that underwent im-
plant placement or apicectomies. This might be due to the considerably lower number of 
patients that underwent implant placement or apicectomies. Another reason could be that 
the wound can be closed primarily after these operations, which is not always possible after 
(surgical) extractions.  
The baseline characteristics were not entirely equal between the groups with and without 
anticoagulant therapy, with a significant difference found in mean age at the time of treat-
ment. This was due to the fact that elderly patients more often use anticoagulant therapy and 
therefore were more often included in the therapy group. We estimate that this difference in 
mean age did not influence the results because the bleeding tendency in the control group is 
not expected to be different when the mean age would have been higher.
Conclusions
The present study analysed the frequency and severity of postoperative bleeding after den-
toalveolar surgery in patients with and without anticoagulant therapy. None of the patients 
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suffered from severe postoperative bleeding. Mild postoperative bleeding incidents that were 
stopped by the patients themselves occurred more often in the patients on anticoagulant 
therapy; however this difference between groups was not statistically significant. Therefore, 
we conclude that it is safe to perform dentoalveolar surgery without stopping anticoagulant 
therapy, provided that the conditions described in the ACTA guidelines are met.
Acknowledgements
The authors are grateful to M. Piersma-Wichers for her assistance during this study. 
104
References
[1] JD Douketis, AC Spyropoulos, FA Spencer, 
M Mayr, AK Jaffer, MH Eckman, AS Dunn, R 
Kunz, American College of Chest Physicians. 
Perioperative management of antithrombotic 
therapy: Antithrombotic Therapy and 
Prevention of Thrombosis, 9th ed: American 
College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest. 
2012;141:e326S-50S. 
[2] W Ageno, AS Gallus, A Wittkowsky, 
M Crowther, EM Hylek, G Palareti, 
American College of Chest Physicians. Oral 
anticoagulant therapy: Antithrombotic 
Therapy and Prevention of Thrombosis, 9th 
ed: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines. 
Chest. 2012;141:e44S-88S. 
[3] PB Lockhart, J Gibson, SH Pond, J Leitch. 
Dental management considerations for the 
patient with an acquired coagulopathy. Part 
2: Coagulopathies from drugs. Br Dent J. 
2003;195:495-501. 
[4] DE van Diermen, IH Aartman, JA 
Baart, J Hoogstraten, I van der Waal. 
Dental management of patients using 
antithrombotic drugs: critical appraisal of 
existing guidelines. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod. 2009;107:616-
24. 
[5] DE van Diermen, JJ Bruers, J Hoogstraten, 
M Bovenlander, A van den Bosch, I van der 
Waal. Treating dental patients who use 
oral antithrombotic medication: a survey 
of dentists in the Netherlands. J Am Dent 
Assoc. 2011;142:1376-82. 
[6]  DE van Diermen, I van der Waal, MW 
Hoogvliets, FN Ong, J Hoogstraten. Survey 
response of oral and maxillofacial surgeons 
on invasive procedures in patients using 
antithrombotic medication. Int J Oral 
Maxillofac Surg. 2013;42:502-7. 
[7] van Diermen D. http://www.acta.nl/en/
Images/Richtlijn%20%20ACTA%20
antistolling%20januari%202012_tcm82-
183934_tcm82-279131.pdf. [31 May 2013; 
in Dutch]. 
[8] JJ Napenas, CH Hong, MT Brennan, SL 
Furney, PC Fox, PB Lockhart. The frequency 
of bleeding complications after invasive 
dental treatment in patients receiving single 
and dual antiplatelet therapy. J Am Dent 
Assoc. 2009;140:690-5. 
[9] MT Brennan, MA Valerin, JL Noll, JJ 
Napenas, ML Kent, PC Fox, HC Sasser, PB 
Lockhart. Aspirin use and post-operative 
bleeding from dental extractions. J Dent Res. 
2008;87:740-4. 
[10] T Lillis, A Ziakas, K Koskinas, A Tsirlis, G 
Giannoglou. Safety of dental extractions 
during uninterrupted single or dual 
antiplatelet treatment. Am J Cardiol. 
2011;108:964-7. 
[11] L Ardekian, R Gaspar, M Peled, B Brener, 
D Laufer. Does low-dose aspirin therapy 
complicate oral surgical procedures?. J Am 
Dent Assoc. 2000;131:331-5. 
[12] C Scully, A Wolff. Oral surgery in patients on 
anticoagulant therapy. Oral Surg Oral Med 






Summary and general discussion
108
Summary
A broad range of topical hemostatic agents is available to the surgeon in case of problematic 
bleeding. Most of these hemostatic agents are based on animal derived products like col-
lagen and gelatin. As these agents carry the potential risk of pathogen transmission, a fully 
synthetic hemostatic agent with at least a comparable efficacy could replace these agents. 
In this thesis, multiple studies on the hemostatic efficacy, mechanical properties and deg-
radation characteristics of synthetic polyurethane foam (PU), based on butane-diisocyanate, 
and with 55 wt% polyethylene glycol (PEG), are described. Furthermore, the incidence and 
severity of bleeding incidents after dentoalveolar surgery has been assessed. 
In chapter 2 the PU foam was tested in vitro and compared to collagen and gelatin hemo-
static agents to analyse if the hemostatic efficacy of these agents could be matched. A test 
model was developed in which human whole blood flowed through the test materials. The 
blood flow deceleration was determined as a derivative for the extent of hemostasis. Several 
modifications were applied to the PU to evaluate if this would increase its hemostatic efficacy. 
The addition of recombinant factor VIIa, phospholipids, adenosine diphosphate and thrombin 
gave no improved results. However, treatment of the PU foams with glow discharge, which 
increased the hydrophilicity of the material, led to increased hemostasis. Increasing the PEG 
concentration of the PU to 55 wt%, and therewith increasing the hydrophilicity of the mate-
rial, also showed improved results that were similar as gelatin. The best results in this study 
were achieved with collagen; these results could not be matched by PU. 
From this study it was concluded that increasing the PEG concentration of the PU is a prom-
ising approach. Therefore, the applicability of PU with 55 wt% PEG as a topical hemostatic 
agent was studied in the subsequent chapters. 
As hemostasis is a complex process which is difficult to simulate in vitro, it was plausible to 
study the hemostatic efficacy of PU in an in vivo model. In chapter 3 a human split-mouth 
model was used to assess the hemostatic efficacy of PU with 55 wt% PEG. In this study 
we included 60 patients who had to undergo extraction of an upper and lower molar. After 
extraction of a molar, a PU foam and collagen or gelatin agent were inserted in separate 
extraction sockets for 2 minutes. At a later stage, the concentration of coagulation param-
eters thrombin-antithrombin III (TAT) complexes, fibrinogen, and thromboxane B2 (TxB2) in 
blood extracts from the agents was measured. The concentrations were also determined 
in baseline blood samples which were collected from the extraction socket. In all materials 
the concentrations of TAT and TxB2 were significantly increased, and fibrinogen concentra-
tion was significantly reduced compared to baseline wound blood concentrations indicating 
increased hemostasis supplementary to the activation induced by the wound area. No sig-
nificant differences were seen in these concentrations of the coagulation parameters in the 
three different hemostatic agents. These results suggest that the hemostatic efficacy of PU is 
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equal to collagen and gelatin and thus forms a promising alternative for these animal-derived 
hemostatic agents.
In chapter 4, we compared the hemostatic efficacy of PU with other hemostatic agents in 
a rat tail-tip model. This study was performed to obtain an overview of the differences in 
time to hemostasis between the most widely used topical hemostatic agents. Furthermore, 
we tested PU enriched with the procoagulant substance chitosan to evaluate if this could 
increase its hemostatic efficacy.
 In 80 rats a similar wound was created at the tail tip which was coagulated with a hemostatic 
agent. The tail tip was fixed on a developed test device to ensure a constant and equal pres-
sure of the test material on the wound. The mean bleeding time was determined and com-
pared between the groups. PU with chitosan showed the shortest mean bleeding time. This 
was significantly shorter than collagen, oxidised regenerated cellulose and chitosan dressing. 
The difference between PU with and without chitosan was not statistically significant. Our 
findings suggest that the hemostatic efficacy of PU is equal to the most widely used hemo-
static agents. The addition of a procoagulant substance like chitosan showed a tendency 
towards shorter bleeding times but did not lead to a significantly faster hemostasis.
In chapter 5, we investigated the mechanism of hemostatic action of PU and compared 
this to collagen and gelatin. Furthermore, the viscoelastic properties of these materials were 
assessed. The hemostatic action mechanism of the materials was tested by analysing the ef-
fect on thrombocyte aggregation in human whole blood and measuring the coagulation time 
of platelet-poor plasma. The ability of the hemostatic agent to exert pressure on the wound 
was quantified in terms of its viscoelastic properties both under dry and wet conditions using 
a low load compression tester. The low amount of free thrombocytes in the blood samples 
of PU and collagen indicates that these materials lead to a high amount of aggregated and 
adhered thrombocytes. The amount of free thrombocytes in the blood samples of gelatin 
showed no significant difference from the control group. The mean coagulation times of the 
platelet-poor plasma samples that were incubated with PU and collagen were significantly 
lower than in the control samples without material, indicating that these materials initiate 
the coagulation cascade. The mean coagulation time of the samples that were incubated 
with gelatin did not differ significantly from the control samples without material. Analysis 
of the viscoelastic properties revealed that the deformation under wet conditions of collagen 
and gelatin is higher than the deformation of PU. Furthermore, the percentage of stress re-
laxation was lowest for PU followed by collagen and gelatin indicating that PU has the highest 
springback capability. From this study we concluded that PU and collagen initiate hemostasis 
through both thrombocyte aggregation and contact activation of the coagulation cascade 
whereas gelatin did not show improved thrombocyte aggregation or initiation of the coagu-
lation cascade. PU has favorable viscoelastic properties compared to collagen and gelatin, 
which leads to better handling capacities and enhanced pressure on a wound.
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The degradation process and time of PU was studied and compared to collagen and gelatin 
in chapter 6. The materials were implanted subcutaneously in rats and rabbits that were 
sacrificed at certain time intervals up to three years. Renal functions of the animals were de-
termined to analyse the possible nefrotoxicity of PEG. The materials, which were explanted at 
the different time intervals, were evaluated with light microscopy. This examination showed 
a comparable pattern of degradation for the test materials. However, the degradation process 
was completed remarkably faster for collagen and gelatin than for PU as PU particles were 
detectible in the samples up to 2.5 years. All of the materials showed a good biocompatibility 
and no inflammatory reactions or severe foreign body reactions occurred. Mean urea and 
creatinine values stayed within the normal range during the three year investigation period 
indicating that the implanted amount of PEG does not lead to nefrotoxicity. Based on these 
results we conclude that PU can be used as a topical hemostatic agent although a shorter 
degradation period would be desirable.
In chapter 7, we evaluated the bleeding incidence after dentoalveolar surgery in patients 
with and without anticoagulant therapy. We included 206 patients: 103 without anticoagu-
lant therapy and 103 with anticoagulant therapy [71 with thrombocyte aggregation inhibi-
tors (TAIs) and 32 with vitamin K antagonists (VKAs)]. Patients were treated according to a 
guideline developed at the Academic Centre for Dentistry Amsterdam (ACTA), the Nether-
lands. The patients underwent surgical extraction, non-surgical extraction, apicoectomy, or 
implant placement. They received standard postoperative care and patients taking VKAs used 
tranexamic acid mouthwash postoperatively which has an antifibrinolytic effect. None of the 
patients experienced severe bleeding requiring medical intervention. In the anticoagulant 
therapy group, seven patients (6.8%) suffered from a mild post-operative bleeding. In the 
control group without anticoagulant therapy, two patients (1.9%) experienced mild post-
operative bleeding. These mild post-operative bleeding incidents could be controlled by the 
patients themselves with compressive gauze. From this study it was concluded that it is safe 
to perform dentoalveolar surgery in patients receiving anticoagulant therapy, provided that 
the conditions described in the ACTA guideline are met.
General discussion
Hemostatic efficacy is the most important property of a topical hemostatic agent. Addi-
tional properties are handling characteristics, bioresorption potential, absence of antigenic 
response, and tissue reactivity effects. The studies described in this thesis demonstrate that 
a synthetic topical hemostatic agent based on polyurethane (PU) comprising polyethylene 
glycol (PEG) has favorable hemostatic, mechanical and tissue reactivity properties. The biore-
sorption potential is promising although the degradation time is remarkably longer than the 
currently used topical hemostatic agents. 
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Hemostatic efficacy of polyurethane foam with 55 wt% polyethylene glycol
The in vitro analysis on hemostatic efficacy showed that PU foam has hemostatic potential 
although the results of collagen could not be matched (chapter 2). In chapter 5, the mecha-
nism of hemostatic action of PU, collagen and gelatin was investigated in vitro by evaluating 
the effect on thrombocyte aggregation and the coagulation cascade. In this study, collagen 
and PU both showed a comparable effect on thrombocyte aggregation but collagen showed 
a faster initiation of the coagulation cascade. In both in vitro studies, the results of gelatin fell 
short compared to collagen and PU. The good results of PU in these studies could be attrib-
uted to the high concentration of PEG as this increased the absorbability and hydrophilicity 
of the material. The absorbable properties might enhance concentration of the endogenous 
coagulation factors and platelets as the effect of cellulose- and polysaccharide-based hemo-
stats is also based partly on this mechanism [1,2]. Increasing the hydrophilicity of polyeth-
ylene has also shown to enhance platelet adhesion and activation of the clotting system [3]. 
The good hemostatic properties of the PU foams that were treated with glow discharge in 
chapter 2 are a further indication that increasing the hydrophilicity of the material leads to a 
better hemostatic efficacy. The use of PEG in the form of hydrogels has already been success-
fully used in surgery to accomplish hemostasis [4,5]. Its mechanism of action in this form 
depends on mechanically sealing the areas of blood leakage [6].
The good results of collagen in these in vitro studies can be largely explained by its action 
mechanism which is based predominantly on platelet aggregation. The collagen attracts 
platelets when they get into contact with blood. The platelets adhere to collagen fibrils and 
degranulate, thereby triggering platelet aggregation [7,8]. This does however not explain the 
short coagulation time of platelet poor plasma after it was incubated with collagen in chap-
ter 5. Our findings suggest that the hemostatic efficacy of collagen also arises out of initia-
tion of the coagulation cascade. This has been described earlier in the literature when it was 
shown that factor XII can be activated by collagen in platelet poor plasma and thus can lead 
to coagulation through initiation of the coagulation cascade [9]. 
The poor results of gelatin are remarkable as it is a commonly used hemostatic agent with 
good hemostatic results [10]. The action mechanism of gelatin is posed to be mostly me-
chanical and seems likely to involve physical surface effects rather than any action on the 
blood clotting mechanism [7,8]. A previous in vitro study also showed very low platelet depo-
sition for gelatin when the material was exposed to platelet rich plasma [11]. The poor results 
of gelatin could therefore indicate that the complexity of the coagulation cascade was not 
adequately imitated in these in vitro studies. 
In our human in vivo study (chapter 3), hemostatic efficacy was examined by measuring 
different coagulation parameters in a split-mouth model. Between the PU foam and gela-
tin- or collagen-based materials no significant differences were seen in these coagulation 
parameters. 
The significant differences between the baseline blood values and the values in the blood 
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extracts from the materials showed that all tested materials increased hemostasis. The co-
agulation cascade was already initiated in the baseline samples as these were taken from a 
wound [12]. The measurement of thrombin-antithrombin III (TAT) complexes and fibrinogen 
gave us an indication of the additional effect of the materials on the coagulation cascade. 
At the end stage of this cascade, fibrinogen is converted into fibrin under the influence of 
thrombin [12]. The increase in TAT complexes and reduction of fibrinogen compared to base-
line values showed that PU, gelatin and collagen substantially increased hemostasis through 
the coagulation cascade. Thromboxane B2 (TxB2) is an inactive metabolite of thromboxane 
A2 which can be used to quantify platelet aggregation [13]. The high TxB2 values in the blood 
extracts from the tested materials show that they also have a substantial effect on platelet 
aggregation. The good in vivo results of gelatin, compared to the in vitro studies, show that 
this material does perform a functional role in hemostasis which apparently is difficult to 
measure in vitro. This was confirmed in chapter 4 where we described an animal in vivo 
study on the hemostatic efficacy of PU compared to the most widely used topical hemostatic 
agents. In this study we also observed only minor differences in hemostatic efficacy between 
the topical hemostatic agents.
Gelatin and collagen are together with oxidized regenerated cellulose traditionally the most 
widely used hemostatic agents in surgery [8]. Oxidized regenerated cellulose was not tested 
in chapter 3 because the structure of the material made it impossible to extract plasma 
samples that could be used for measurement of the coagulation parameters. In chapter 
4 the oxidized regenerated cellulose could be included together with gelatin, collagen and 
a chitosan dressing to be compared with PU. The relatively equal results of the materials in 
chapter 3 and chapter 4 are consistent with other studies that could not demonstrate dif-
ferences in hemostatic efficacy between these widely used hemostatic agents [14-16]. There 
are however some studies that designated collagen as the most effective topical hemostatic 
agent which corresponds to our findings in chapter 2 [11,17]. Other studies found chitin to 
be the most effective topical hemostatic agent [18,19]. These studies and other reports on 
the good hemostatic efficacy of the chitosan dressing HemCon [20,21] led to the decision to 
include this material in the study described in chapter 4 and to analyse if the addition of chi-
tosan to PU could increase its hemostatic efficacy. The addition of chitosan could not signifi-
cantly improve the hemostatic efficacy of PU which could be caused by mixing the chitosan 
through the foam. As a result the chitosan concentration at the surface of the foam might 
not have been high enough to exert an additional effect. The chitosan dressing HemCon 
showed a bleeding time that was significantly longer than gelatin and PU with chitosan. This 
discrepancy from earlier studies might be explained by the hemostatic action mechanism of 
HemCon. This material becomes sticky upon contact with blood and creates an enhanced 
tissue adhesion [22]. This working mechanism was probably disadvantageous in the used 
test model because the material had to be removed from the wound regularly to analyse if 
the wound was dry. The sticky property of the chitosan could have led to partial removal of 
the blood clot and thus a longer bleeding time. 
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Besides the surface reaction of a hemostatic material with blood components, compres-
sion of a wound is known to be effective and important for hemostasis [23]. Therefore, it 
is important that a topical hemostatic agent keeps its firmness and shape after it is soaked 
with blood. The results in chapter 5 showed that the mechanical stability of collagen and 
gelatin foam significantly decreased after getting soaked, whereas PU foam maintained its 
stability. Furthermore, PU showed the highest amount of springback and therefore will keep 
more pressure on a wound even after getting soaked with blood. Collagen and especially 
gelatin become mushy and formless under wet conditions and are therefore less likely to 
exert enough pressure on a wound. The more firm PU also ensures better handling capaci-
ties than the mushy and formless collagen and gelatin. We did not find any indications for 
possible compressive complications due to extreme swelling of gelatin and collagen which is 
often mentioned in the literature [4,8,24,25]. The poor viscoelastic properties of gelatin are 
probably due to the production process in which denaturation of collagen leads to breaking 
of the triple-helix structure [26]. The better viscoelastic properties of collagen compared to 
gelatin were also observed in another study [27]. 
Degradation characteristics of polyurethane foam with 55 wt% polyethylene glycol
Increasing the PEG concentration to 55 wt% and therewith increasing the hydrophilicity of 
the polyurethane led to a better hemostatic efficacy in chapter 2. Another advantage of the 
increased hydrophilicity is the presence of a greater volume of water within the polyurethane 
which allows for a greater amount of hydrolysis to take place [28,29]. In chapter 6 it was 
demonstrated that the initial degradation of PU with a high percentage of PEG occurred more 
rapidly compared to PU without PEG [30]. However, the total degradation time was nearly 
identical with detectible PU remnants up to 2.5 years after implantation. A further increase 
in PEG will probably not lead to a faster overall degradation period and might lead to a weak 
and tacky material with inferior viscoelastic properties (chapter 5) [31]. Other studies have 
tried to increase the rate of degradation by inserting enzyme sensitive linkages in the hard 
segment of the PU [31-33]. This led to an increased susceptibility to enzyme-mediated but 
not buffer-mediated erosion when compared to a control PU [28].
The PU with 55 wt% PEG has shown no severe inflammatory, (nefro-)toxic or foreign body re-
sponse during the complete process of degradation (chapter 6). This is in accordance with other 
studies that analysed the biocompatibility of PU [30,34]. The degradation periods of collagen 
and gelatin were considerably faster with remnants of gelatin seen up to 12 weeks after implan-
tation and traceable remnants of collagen up to 26 weeks after implantation (chapter 6). These 
short degradation periods of collagen and gelatin are confirmed by the literature [8,35,36]. 
Postoperative bleeding in patients taking anticoagulants
Chapter 7 showed that anticoagulants can be safely continued in patients who need to 
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undergo dentoalveolar surgery. Prerequisite for this is that the recommendations from the 
ACTA guideline are followed. Important recommendations are the maximum value of 3.5 
for the international normalized ratio (INR) and the postoperative use of the antifibrinolytic 
agent tranexamic acid in patients on vitamin K inhibitors. These recommendations are based 
on publications by van Diermen et al. [37-40] and are supported by several other studies 
[41-43]. Especially in oral surgery, patients might benefit from the use of tranexamic acid 
as the oral mucosa and saliva are rich in plasminogen activators [44]. The consensus that 
the oral anticoagulant regimen can be maintained in patients who undergo oral surgery is 
confirmed by this thesis (chapter 7) [45]. The use of other topical hemostatic agents like 
collagen and gelatin is not routinely recommended in patients taking oral anticoagulants but 
are mainly used in cases of postoperative bleeding or prolonged bleeding time [46,47]. The 
results from chapter 7 showed that, when the recommendations from the ACTA guideline 
are followed, no severe postoperative bleeding incidents occurred which required medical 
treatment including the use of topical hemostatic agents. Mild postoperative bleeding inci-
dents, which required compression with a gauze by the patients themselves, predominantly 
occurred in patients using oral anticoagulants who had to undergo one or more surgical 
extractions. There might be a role for topical hemostatic agents in preventing these mild 
bleeding incidents. Routinely inserting topical hemostatic agents in the extraction socket 
after surgical extraction in patients using anticoagulants could reduce the amount of mild 
bleeding incidents. Moreover, the continuation of oral anticoagulants during oral surgery is 
also advocated for patients receiving dual thrombocyte aggregation inhibitor therapy [48]. 
This could lead to a further increase of the incidence of mild and possible severe postopera-
tive bleeding incidents [49]. 
Future perspectives
The studies in this thesis demonstrated that PU foam with 55 wt% PEG has a hemostatic ef-
ficacy that is comparable to the most widely used hemostatic agents. Hemostasis by the PU 
foam is induced by initiation of the coagulation cascade and platelet aggregation and its vis-
coelastic properties are favorable compared to collagen and gelatin. Significantly increasing 
the hemostatic efficacy of PU by the addition of procoagulant substances was not successful 
in the tests on this subject that were described in this thesis. However, we estimate that the 
addition of procoagulant substances should be able to improve the hemostatic efficacy of PU, 
since collagen and gelatin to which a procoagulant substance like thrombin has been added 
have shown an enhanced hemostatic efficacy [50].
The PU with 55 wt% PEG has shown to be a material that can be safely used as a biodegrad-
able implant. Its degradation time could however not approach the degradation times of 
collagen and gelatin. The solution to this issue could be found in alteration of the hard seg-
ments of the polyurethane which are composed of butanediol and 1,4-butanediisocyanate. 
This could be done by introducing an enzyme sensitive linkage as has been described in other 
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studies [31-33]. Another option could be alteration of the chain length of the urethane moi-
eties. The currently tested polymer was composed of 5 urethane moieties whereas a length 
of 3 urethane moieties might lead to a more rapid degradation period. Future research will 
have to show if these possible changes in the hard segments can increase the rate of degra-
dation while maintaining the hemostatic and mechanical properties of the foam. 
The number of patients on anticoagulant therapy that need to undergo dentoalveolar surgery 
will probably increase in the upcoming years as cardiac diseases are becoming more frequent 
in our aging society [51]. The role of hemostatic agents is not clearly established in these pa-
tients as can be deduced from the rapidly changing guidelines on this subject. The antifibri-
nolytic agent tranexamic agent will probably maintain a major role in patients using vitamin 
K inhibitors, although the effective concentration and the necessary length of postoperative 




[1] D Zhu. Mathematical modeling of blood 
coagulation cascade: kinetics of intrinsic and 
extrinsic pathways in normal and deficient 
conditions. Blood Coagul Fibrinolysis. 
2007;18:637-46. 
[2] M Kanko, T Liman, S Topcu. A low-cost and 
simple method to stop intraoperative leakage-
type bleeding: use of the vancomycin-
oxidized regenerated cellulose (ORC) 
sandwich. J Invest Surg. 2006;19:323-7. 
[3] HT Spijker, R Bos, HJ Busscher, T van 
Kooten, W van Oeveren. Platelet adhesion 
and activation on a shielded plasma gradient 
prepared on polyethylene. Biomaterials. 
2002;23:757-66. 
[4] HE Achneck, B Sileshi, RM Jamiolkowski, 
DM Albala, ML Shapiro, JH Lawson. A 
comprehensive review of topical hemostatic 
agents: efficacy and recommendations for 
use. Ann Surg. 2010;251:217-28. 
[5] MM Saunders, ZC Baxter, A Abou-Elella, 
AR Kunselman, JC Trussell. BioGlue and 
Dermabond save time, leak less, and are 
not mechanically inferior to two-layer and 
modified one-layer vasovasostomy. Fertil 
Steril. 2009;91:560-5. 
[6] WF Konertz, M Kostelka, FW Mohr, R 
Hetzer, M Hubler, J Ritter, J Liu, C Koch, JE 
Block. Reducing the incidence and severity 
of pericardial adhesions with a sprayable 
polymeric matrix. Ann Thorac Surg. 
2003;76:1270,4; discussion 1274. 
[7] H Seyednejad, M Imani, T Jamieson, AM 
Seifalian. Topical haemostatic agents. Br J 
Surg. 2008;95:1197-225. 
[8] C Schonauer, E Tessitore, G Barbagallo, 
V Albanese, A Moraci. The use of local 
agents: bone wax, gelatin, collagen, oxidized 
cellulose. Eur Spine J. 2004;13 Suppl 1:S89-
96. 
[9] GD Wilner, HL Nossel, EC LeRoy. Activation 
of Hageman factor by collagen. J Clin Invest. 
1968;47:2608-15. 
[10] JS Bellet, AM Wagner. Difficult-to-control 
bleeding. Pediatr Dermatol. 2009;26:559-62. 
[11] WR Wagner, JM Pachence, J Ristich, PC 
Johnson. Comparative in vitro analysis 
of topical hemostatic agents. J Surg Res. 
1996;66:100-8. 
[12] EW Davie, K Fujikawa, W Kisiel. 
The coagulation cascade: initiation, 
maintenance, and regulation. Biochemistry. 
1991;30:10363-70. 
[13] S Kamath, AD Blann, GY Lip. Platelet 
activation: assessment and quantification. 
Eur Heart J. 2001;22:1561-71. 
[14] BS Kheirabadi, A Field-Ridley, R Pearson, M 
MacPhee, W Drohan, D Tuthill. Comparative 
study of the efficacy of the common topical 
hemostatic agents with fibrin sealant in a 
rabbit aortic anastomosis model. J Surg Res. 
2002;106:99-107. 
[15] YM Hong, KR Loughlin. The use of 
hemostatic agents and sealants in urology. J 
Urol. 2006;176:2367-74. 
[16] LP Msezane, MH Katz, ON Gofrit, AL 
Shalhav, KC Zorn. Hemostatic agents and 
instruments in laparoscopic renal surgery. J 
Endourol. 2008;22:403-8. 
[17] JM Alexander, JL Rabinowitz. Microfibrillar 
collagen (Avitene) as a hemostatic agent 
in experimental oral wounds. J Oral Surg. 
1978;36:202-5. 
[18] SD Schwaitzberg, MW Chan, DJ Cole, M 
Read, T Nichols, D Bellinger, RJ Connolly. 
Comparison of poly-N-acetyl glucosamine 
with commercially available topical 
hemostats for achieving hemostasis in 
coagulopathic models of splenic hemorrhage. 
J Trauma. 2004;57:S29-32. 
[19] MW Chan, SD Schwaitzberg, M Demcheva, 
J Vournakis, S Finkielsztein, RJ Connolly. 
Comparison of poly-N-acetyl glucosamine 
(P-GlcNAc) with absorbable collagen 
(Actifoam), and fibrin sealant (Bolheal) 
for achieving hemostasis in a swine 
model of splenic hemorrhage. J Trauma. 
2000;48:454,7; discussion 457-8. 
[20] I Wedmore, JG McManus, AE Pusateri, JB 
Holcomb. A special report on the chitosan-
based hemostatic dressing: experience 
in current combat operations. J Trauma. 
117
2006;60:655-8. 
[21] MA Brown, MR Daya, JA Worley. Experience 
with chitosan dressings in a civilian EMS 
system. J Emerg Med. 2009;37:1-7. 
[22] HB Alam, D Burris, JA DaCorta, P Rhee. 
Hemorrhage control in the battlefield: 
role of new hemostatic agents. Mil Med. 
2005;170:63-9. 
[23] RT Niemczura, RG DePalma. Optimum 
compress temperature for wound 
hemostasis. J Surg Res. 1979;26:570-3. 
[24] PO Larson. Topical hemostatic agents for 
dermatologic surgery. J Dermatol Surg Oncol. 
1988;14:623-32. 
[25] MD Palm, JS Altman. Topical hemostatic 
agents: a review. Dermatol Surg. 
2008;34:431-45. 
[26] A Bigi, G Cojazzi, S Panzavolta, K Rubini, N 
Roveri. Mechanical and thermal properties 
of gelatin films at different degrees of 
glutaraldehyde crosslinking. Biomaterials. 
2001;22:763-8. 
[27] CN Grover, JH Gwynne, N Pugh, S Hamaia, 
RW Farndale, SM Best, RE Cameron. 
Crosslinking and composition influence the 
surface properties, mechanical stiffness and 
cell reactivity of collagen-based films. Acta 
Biomater. 2012;8:3080-90. 
[28] GA Skarja, KA Woodhouse. In vitro 
degradation and erosion of degradable, 
segmented polyurethanes containing an 
amino acid-based chain extender. J Biomater 
Sci Polym Ed. 2001;12:851-73. 
[29] JD Fromstein, KA Woodhouse. Elastomeric 
biodegradable polyurethane blends for soft 
tissue applications. J Biomater Sci Polym Ed. 
2002;13:391-406. 
[30] B van Minnen, MB van Leeuwen, G Kors, J 
Zuidema, TG van Kooten, RR Bos. In vivo 
resorption of a biodegradable polyurethane 
foam, based on 1,4-butanediisocyanate: a 
three-year subcutaneous implantation study. 
J Biomed Mater Res A. 2008;85:972-82. 
[31] GA Skarja, KA Woodhouse. Structure-
Property Relationships of Degradable 
Polyurethane Elastomers Containing an 
Amino Acid-Based Chain Extender. J Appl 
Polym Sci. 2000;75:1522-34. 
[32] GA Skarja, KA Woodhouse. Synthesis and 
characterization of degradable polyurethane 
elastomers containing and amino acid-based 
chain extender. J Biomater Sci Polym Ed. 
1998;9:271-95. 
[33] SL Elliott, JD Fromstein, JP Santerre, KA 
Woodhous. Identification of biodegradation 
products formed by L-phenylalanine based 
segmented polyurethaneureas. J Biomater Sci 
Polym Ed. 2002;13:691-711. 
[34] JP Santerre, K Woodhouse, G Laroche, RS 
Labow. Understanding the biodegradation 
of polyurethanes: from classical implants to 
tissue engineering materials. Biomaterials. 
2005;26:7457-70. 
[35] JM Pachence. Collagen-based devices for 
soft tissue repair. J Biomed Mater Res. 
1996;33:35-40. 
[36] C Alpaslan, GH Alpaslan, T Oygur. Tissue 
reaction to three subcutaneously implanted 
local hemostatic agents. Br J Oral Maxillofac 
Surg. 1997;35:129-32. 
[37] DE van Diermen, IH Aartman, JA 
Baart, J Hoogstraten, I van der Waal. 
Dental management of patients using 
antithrombotic drugs: critical appraisal of 
existing guidelines. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod. 2009;107:616-
24. 
[38] DE van Diermen, JJ Bruers, J Hoogstraten, 
M Bovenlander, A van den Bosch, I van der 
Waal. Treating dental patients who use 
oral antithrombotic medication: a survey 
of dentists in the Netherlands. J Am Dent 
Assoc. 2011;142:1376-82. 
[39] DE van Diermen, I van der Waal, J 
Hoogstraten. Management recommendations 
for invasive dental treatment in patients 
using oral antithrombotic medication, 
including novel oral anticoagulants. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 
2013;116:709-16. 
[40] DE van Diermen, I van der Waal, MW 
Hoogvliets, FN Ong, J Hoogstraten. Survey 
response of oral and maxillofacial surgeons 
 CHAPTER 8
118
on invasive procedures in patients using 
antithrombotic medication. Int J Oral 
Maxillofac Surg. 2013;42:502-7. 
[41] G Borea, L Montebugnoli, P Capuzzi, C 
Magelli. Tranexamic acid as a mouthwash in 
anticoagulant-treated patients undergoing 
oral surgery. An alternative method to 
discontinuing anticoagulant therapy. Oral 
Surg Oral Med Oral Pathol. 1993;75:29-31. 
[42] G Ramstrom, S Sindet-Pedersen, G Hall, 
M Blomback, U Alander. Prevention of 
postsurgical bleeding in oral surgery using 
tranexamic acid without dose modification of 
oral anticoagulants. J Oral Maxillofac Surg. 
1993;51:1211-6. 
[43] S Sindet-Pedersen, G Ramstrom, S Bernvil, M 
Blomback. Hemostatic effect of tranexamic 
acid mouthwash in anticoagulant-treated 
patients undergoing oral surgery. N Engl J 
Med. 1989;320:840-3. 
[44] PM Mannucci. Hemostatic drugs. N Engl J 
Med. 1998;339:245-53. 
[45]  JC Souto, A Oliver, I Zuazu-Jausoro, A 
Vives, J Fontcuberta. Oral surgery in 
anticoagulated patients without reducing 
the dose of oral anticoagulant: a prospective 
randomized study. J Oral Maxillofac Surg. 
1996;54:27,32; discussion 323. 
[46]  T Lillis, A Ziakas, K Koskinas, A Tsirlis, G 
Giannoglou. Safety of dental extractions 
during uninterrupted single or dual 
antiplatelet treatment. Am J Cardiol. 
2011;108:964-7. 
[47] C Scully, A Wolff. Oral surgery in patients on 
anticoagulant therapy. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 2002;94:57-
64. 
[48] DE van Diermen. Oral antithrombotics 
and dentistry: Current state of affairs and 
guideline proposal. Ph.D. Thesis University 
of Amsterdam, the Netherlands. 2013. 
[49] C Girotra, M Padhye, G Mandlik, A Dabir, 
M Gite, R Dhonnar, V Pandhi, M Vandekar. 
Assessment of the risk of haemorrhage and 
its control following minor oral surgical 
procedures in patients on anti-platelet 
therapy: a prospective study. Int J Oral 
Maxillofac Surg. 2014;43:99-106. 
[50] MC Oz, JF Rondinone, NS Shargill. FloSeal 
Matrix: new generation topical hemostatic 
sealant. J Card Surg. 2003;18:486-93. 
[51] M Torn, WL Bollen, FJ van der Meer, EE 
van der Wall, FR Rosendaal. Risks of oral 
anticoagulant therapy with increasing age. 






Lokale hemostatica zijn hulpmiddelen die ter plaatse van een wond de bloedstolling bevor-
deren. Ze kunnen worden gebruikt bij patiënten die een bloeding hebben als gevolg van een 
trauma of stoornis in de bloedstolling. Middelen om bloedingen te stoppen worden al dui-
zenden jaren gebruikt. 
Tegenwoordig worden lokale hemostatica in alle chirurgische disciplines gebruikt. De he-
mostatica zijn in verschillende soorten en maten beschikbaar. De meeste hemostatica zijn 
geproduceerd op basis van dierlijke materialen als collageen en gelatine. Een nadeel van deze 
materialen is dat ze in natte toestand snel hun mechanische eigenschappen verliezen en 
mogelijk ziekten kunnen overbrengen van dier op mens. Een synthetisch hemostaticum met 
goede visco-elastische eigenschappen op basis van polyurethaan (PU) en polyethyleenglycol 
(PEG) zou deze nadelen kunnen wegnemen. Daarnaast is het productieproces bij een syn-
thetisch materiaal veel beter te controleren en waar nodig aan te passen. Het PU dat in dit 
proefschrift is beschreven is samengesteld uit niet-toxische componenten die afbreekbaar 
zijn door het menselijk lichaam waardoor het veilig gebruikt kan worden. Dit in tegenstelling 
tot bijvoorbeeld het polyurethaanschuim dat gebruikt wordt voor de isolatie van gebouwen.
Het doel van dit promotieonderzoek was te komen tot een klinisch toepasbaar synthetisch 
hemostaticum op basis van PU en PEG. Hiervoor is onderzocht of de hemostatische effecti-
viteit van het materiaal tenminste gelijk is aan de effectiviteit van de bestaande materialen. 
Verder is onderzocht hoe snel het materiaal oplost in vergelijking met collageen en gelatine. 
Ook is er een hoofdstuk opgenomen waarin de effecten op nabloedingen worden geëvalueerd 
van het doorgebruiken van anticoagulantia (bloedverdunners) tijdens een operatieve ingreep 
in de mond.
In hoofdstuk 2 is een studie beschreven waarbij in een testopstelling in het laboratorium het 
PU schuim is vergeleken met collageen en gelatine. In deze testopstelling stroomde humaan 
(menselijk) bloed door de testmaterialen. De afname van de stroomsnelheid van het bloed 
werd bepaald als afgeleide voor de mate van bloedstolling. Er werden verschillende aanpas-
singen aan het PU gedaan om te evalueren of hiermee de hemostatische effectiviteit van het 
materiaal kon worden verbeterd. Het toevoegen van stollingsfactor VIIa, fosfolipiden, adeno-
sine difosfaat en trombine zorgde niet voor een verbeterde bloedstolling. Behandeling van 
de PU met ‘plasma glow discharge’ (plasma glimontlading) gaf wel een betere bloedstolling. 
Deze behandeling wordt toegepast om biomaterialen, waaronder polyurethaan, meer hydro-
fiel te maken. Ook het verhogen van de PEG concentratie naar 55 wt% (gewichtsprocent), en 
daarmee de hydrofiliciteit van het materiaal, zorgde voor betere resultaten die vergelijkbaar 
waren met gelatine. In deze studie werden de beste resultaten behaald met collageen, bij welk 
materiaal de afname van de stroomsnelheid van het bloed significant sneller was dan bij PU.
Uit deze studie werd geconcludeerd dat het verhogen van de PEG concentratie in het PU 
schuim een veelbelovende aanpak is. Daarom is de effectiviteit en oplosbaarheid van dit ma-
teriaal verder onderzocht in de volgende hoofdstukken.
Omdat de bloedstolling in een testopstelling in het laboratorium (in vitro) niet volledig is na 
te bootsen, zijn er ook studies gedaan bij mensen en dieren. Deze studies worden in vivo 
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studies genoemd en in hoofdstuk 3 is een dergelijke studie beschreven. Hierbij zijn 60 pa-
tiënten geïncludeerd waarbij een kies in de boven- en onderkaak moest worden verwijderd. 
Nadat de kiezen eruit gehaald waren, is het PU schuim in de ene wond en een collageen- of 
gelatinespons in de andere wond gedaan gedurende 2 minuten. Op deze manier kon het 
PU schuim met collageen en gelatine worden vergeleken in eenzelfde patiënt. Nadat het 
testmateriaal zich gedurende 2 minuten had kunnen volzuigen met bloed werd het uit de 
wond gehaald en afgedraaid in een centrifuge, zodat metingen konden worden gedaan aan 
het bloed uit de testmaterialen. In dit bloed zijn de concentraties van trombine-antitrombine 
III (TAT) complexen, fibrinogeen en tromboxaan B2 (TxB2) gemeten om informatie te krijgen 
over de mate van stolling in de verschillende testmaterialen. Deze concentraties werden ook 
bepaald in bloedmonsters die uit de wond werden opgezogen om een basiswaarde te krijgen. 
Uit de metingen bleek dat de concentraties van de TAT complexen en TxB2 significant hoger 
waren, en de fibrinogeenconcentratie significant lager was dan de concentraties in het bloed 
dat rechtstreeks uit de wond was gezogen. Hieruit bleek dat er toegenomen bloedstolling was 
in de materialen bovenop de activatie van de bloedstolling in de wond door het lichaam zelf. 
Er werden geen significante verschillen gezien tussen de testmaterialen onderling. Uit deze 
resultaten werd geconcludeerd dat de hemostatische effectiviteit van PU schuim, gelijk is 
aan collageen en gelatine en daardoor een veelbelovend synthetisch alternatief is voor deze 
producten die op basis van dierlijke materialen vervaardigd zijn.
Ook in hoofdstuk 4 is een in vivo studie beschreven. In deze studie werden verschillende 
hemostatica vergeleken met het PU schuim door ze te testen in een gestandaardiseerde stol-
lingstest bij ratten. Ook werd PU getest waaraan de stollingsbevorderende stof chitosan was 
toegevoegd om te analyseren of de hemostatische effectiviteit hierdoor kon worden verbeterd. 
In totaal werden 80 ratten gebruikt voor deze studie, hierdoor konden 8 groepen met 10 
ratten worden samengesteld. Bij de ratten werd aan het uiteinde van de staart een wond 
gemaakt nadat de staart op een testopstelling was gefixeerd. De wond werd vervolgens in de 
testopstelling met een constante en gelijke druk door één van de testmaterialen afgedrukt. 
Vervolgens werd de tijd gemeten tot de wond volledig gestold was zodat de gemiddelde stol-
lingstijden met elkaar konden worden vergeleken. 
De tijd tot volledige stolling was 23.9 minuten voor het PU schuim. Dit was niet significant 
korter of langer dan de stollingstijden van gelatine (23.6 min), collageen (28.2 min) en cellu-
lose (26.9 min). Het PU schuim waaraan chitosan was toegevoegd liet de kortste gemiddelde 
stollingstijd zien (21.5 min) maar het verschil met de PU zonder chitosan was niet significant. 
Uit deze studie werd geconcludeerd dat de hemostatische effectiviteit van PU gelijk is aan de 
meest gebruikte hemostatica. Het toevoegen van de stollingsbevorderende stof chitosan liet 
een iets snellere gemiddelde stollingstijd zien, maar het verschil was niet significant.
In hoofdstuk 5 is een studie beschreven naar de stollingsbevorderende eigenschappen van 
PU schuim waarbij dit werd vergeleken met collageen en gelatine. Ook de visco-elastische 
eigenschappen van de materialen werden geanalyseerd door de vervormbaarheid en elas-
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ticiteit onder verschillende omstandigheden te meten. De stollingseigenschappen werden 
getest door het effect op de aggregatie (samenklontering) van bloedplaatjes in humaan bloed 
te meten en het effect op de stollingstijd van bloedplasma zonder bloedplaatjes te bepalen. 
Het vermogen van de materialen om druk uit te kunnen oefenen op de wond werd gekwan-
tificeerd door de visco-elastische eigenschappen te bepalen onder droge en natte condities 
met behulp van een testopstelling. 
Het lage aantal vrije bloedplaatjes in de bloedmonsters van PU schuim en collageen duiden 
erop dat onder invloed van deze materialen een groot gedeelte van de bloedplaatjes samen-
klonteren. Het aantal vrije bloedplaatjes in de bloedmonsters van gelatine verschilde niet 
significant van de bloedmonsters uit de controlegroep. De gemiddelde stollingstijden van de 
plasmamonsters die geïncubeerd waren met PU and collageen waren significant korter dan 
de stollingstijden van de controlemonsters zonder materiaal. Hieruit werd afgeleid dat PU en 
collageen ook zorgen voor initiatie van de stollingscascade. De gemiddelde stollingstijd van 
de plasmamonsters die geïncubeerd waren met gelatine was niet significant verschillend van 
de gemiddelde stollingstijd van de controlemonsters zonder materiaal. Analyse van de visco-
elastische eigenschappen liet zien dat de vervorming onder natte condities van collageen en 
gelatine groter is dan de vervorming van PU schuim. Ook de mate waarin in het materiaal 
terugkeert naar zijn oorspronkelijke vorm nadat het is ingedrukt was groter voor PU dan voor 
collageen en gelatine. 
Uit deze studie werd geconcludeerd dat PU schuim en collageen tot bloedstolling leiden 
doordat deze materialen zorgen voor aggregatie van bloedplaatjes en de stollingscascade ac-
tiveren. Gelatine liet in deze studie geen verbetering zien van aggregatie van bloedplaatjes of 
activatie van de stollingscascade in vergelijking met de controlemonsters. De visco-elastische 
eigenschappen van PU schuim zijn gunstiger dan die van collageen en gelatine omdat het PU 
schuim zijn stevigheid behoudt terwijl collageen en gelatine hun mechanische eigenschap-
pen verliezen. Hierdoor kan er met het PU schuim een betere druk op de wond worden uitge-
oefend en is het in natte toestand beter te hanteren dan collageen en gelatine.
Voor een goed hemostaticum is het van belang dat het snel degradeert (oplost) in het mense-
lijk lichaam en niet leidt tot ontstekingsreacties of ernstige vreemd-lichaam reacties. Daarom 
is een studie gedaan naar de degradatiesnelheid en -eigenschappen van PU schuim waarbij 
weer een vergelijk is gemaakt met collageen en gelatine. Deze studie is beschreven in hoofd-
stuk 6. De materialen werden subcutaan (onderhuids) geïmplanteerd in ratten en konijnen 
die op bepaalde tijdsintervallen tot drie jaar werden getermineerd. De nierfuncties van de 
dieren werden op deze tijdsintervallen gemeten om de mogelijke toxische effecten van PEG 
op de nieren te kunnen analyseren. Na terminatie van de dieren werden de materialen opge-
zocht en uitgenomen waarna ze werden onderzocht met een lichtmicroscoop. 
Uit dit onderzoek bleek dat het patroon van degradatie gelijk was voor de verschillende mate-
rialen. De tijd tot volledige degradatie was echter aanzienlijk korter voor collageen en gelatine 
dan voor PU schuim. Het duurde 3 jaar na implantatie voordat het PU schuim niet meer werd 
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gezien terwijl gelatine en collageen al na respectievelijk 12 en 26 weken niet meer zichtbaar 
waren. Bij geen van de materialen werden ontstekingsreacties of ernstige vreemd-lichaam 
reacties gezien. De nierfuncties van de dieren bleven gedurende de onderzoeksperiode van 
drie jaar binnen de normaalwaarden en het PEG had dus in de gebruikte hoeveelheden geen 
toxische effecten op de nieren. Op basis van deze resultaten werd geconcludeerd dat PU 
schuim veilig gebruikt zou kunnen worden als hemostaticum. Het zou echter gunstiger zijn 
als PU schuim net zo snel zou degraderen als collageen en gelatine.
In hoofdstuk 7 zijn de effecten op nabloedingen geëvalueerd van het doorgebruiken van an-
ticoagulantia tijdens operatieve ingrepen in de mond. Voor deze studie werden 206 patiënten 
geïncludeerd waarvan er 103 geen anticoagulantia gebruikten en 103 wel anticoagulantia 
gebruikten. In de groep patiënten die wel anticoagulantia gebruikten waren er 71 die bloed-
plaatjesremmers gebruikten en 32 die vitamine K antagonisten gebruikten die aangrijpen 
op de stollingscascade. Patiënten werden behandeld volgens een richtlijn die is ontwikkeld 
aan het Academisch Centrum Tandheelkunde Amsterdam (ACTA). De operatieve ingrepen 
in de mond werden verdeeld in de volgende categorieën: chirurgische verwijdering van kie-
zen, niet-chirurgische verwijdering van kiezen, apexresecties (wortelpuntbehandelingen) en 
het plaatsen van implantaten. Alle patiënten kregen standaard postoperatieve zorg en de 
patiënten die vitamine K antagonisten gebruikten moesten daarnaast spoelen met tranexa-
minezuur mondspoeling. Het tranexaminezuur zorgt ervoor dat het bloedstolsel minder snel 
wordt afgebroken in de mond.
Geen van patiënten kreeg een ernstige nabloeding waarvoor medisch ingrijpen noodzakelijk 
was. In de groep met patiënten die anticoagulantia gebruikten waren er zeven patiënten (6.8%) 
die een lichte nabloeding hadden na de ingreep. In de controlegroep met patiënten die geen 
anticoagulantia gebruikten kregen er twee (1.9%) een lichte nabloeding. Deze lichte nabloe-
dingen konden door de patiënten zelf gestelpt worden door een gaasje op de wond te drukken. 
Uit deze studie werd geconcludeerd dat het veilig is om operatieve ingrepen in de mond te 
doen bij patiënten die anticoagulantia gebruiken, mits de ACTA richtlijn gevolgd wordt. 
In hoofdstuk 8 zijn de belangrijkste onderzoeksresultaten besproken, waarbij ook aanbe-
velingen voor toekomstig onderzoek zijn gedaan. Uit dit onderzoek is geconcludeerd dat de 
hemostatische effectiviteit van polyurethaanschuim met 55 wt% polyethyleenglycol gelijk is 
aan de hemostatica op basis van collageen en gelatine. Het toevoegen van stollingsbevorde-
rende stoffen aan het polyurethaanschuim heeft in de beschreven onderzoeken niet geleid 
tot een significant betere stolling. De visco-elastische eigenschappen van polyurethaan zijn 
gunstiger dan die van gelatine en collageen, waardoor er enige compressie op een wond 
kan worden uitgeoefend en het in natte toestand goed te hanteren is. De tijd tot volledige 
degradatie van het PU schuim is langer dan de degradatietijden van collageen en gelatine. 
Verder wordt geconcludeerd dat het veilig is om operatieve ingrepen in de mond te doen bij 





Er zijn veel mensen die door hun hulp en steun hebben bijgedragen aan de totstandkoming 
van dit proefschrift. Een aantal van hen wil ik hier persoonlijk bedanken.
Allereerst wil ik alle patiënten bedanken die bereid zijn geweest deel te nemen aan dit on-
derzoek, zonder jullie was er geen proefschrift geweest. Daarnaast dank aan alle mensen die 
vrijwillig bloed hebben laten afnemen in het lab zodat ik daarmee vervolgens snel testen kon 
gaan doen. 
Prof. dr. R.R.M. Bos, beste Ruud, ergens begin 2007 heb ik als 6e-jaars geneeskundestudent 
jou een e-mail gestuurd met de vraag of ik misschien een keuzeproject bij de kaakchirurgie 
kon doen. Ik kan me nog goed herinneren dat ik blij verrast was door je enthousiaste reac-
tie en uitnodiging om snel langs te komen. Dit enthousiasme kenmerkt jou en heeft, zeker 
als het even tegenzat, erg motiverend gewerkt. In 2011 hebben we het, mede door jouw 
enthousiaste begeleiding, nog bijna tot de finale van de Academische Jaarprijs geschopt. Be-
dankt voor je vertrouwen en fijne begeleiding.
Dr. W. van Oeveren, beste Wim, nadat de eerste contacten waren gelegd via Ruud, ben ik 
bij jou op het lab terecht gekomen om testen te doen met polyurethaanschuim. Ik had me, 
zeker in die eerste periode, geen betere begeleider kunnen voorstellen. Je eindeloze kennis en 
ideeën over mogelijke testen heeft dit onderzoek echt van de grond getild. Door jouw snelle 
en gerichte commentaar heeft het scriptieonderzoek kunnen uitgroeien tot dit proefschrift.
Dr. B. van Minnen, beste Baucke, hoewel het erg voor de hand ligt dat jij, als pionier op het 
gebied van polyurethaanschuim, me nu mede begeleidt is je directe betrokkenheid pas laat 
tot stand gekomen en dan nog voornamelijk door het onderzoek naar het ACTA-protocol. Ik 
ben erg blij dat deze betrokkenheid er nu is want de afgelopen tijd heeft wel duidelijk gemaakt 
dat jouw begeleiding en commentaar zeker een meerwaarde heeft.
Prof. dr. F.K.L. Spijkervet, beste Fred, bedankt voor de mogelijkheid die ik heb gekregen om 
na het onderzoek mijn opleiding tot MKA-chirurg op deze afdeling te volgen. Ik vind het een 
voorrecht de opleiding te mogen doen op een afdeling waar een aangenaam opleidingskli-
maat en een prettige sfeer heerst. 
Prof. dr. L.G.M. de Bont, beste professor, ik ben ook u als voormalig afdelingshoofd dankbaar 
voor de mogelijkheid die u hebt geboden om mijn promotieonderzoek te combineren met de 
studie tandheelkunde. 
Dhr. Rolvink, beste Richard, dank voor je inzet die ervoor gezorgd heeft dat ik het promotie-
onderzoek op een goede en prettige manier heb kunnen afronden.
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Dr. P.K. Sharma, beste Prashant, je hulp en kennis op het gebied van visco-elasticiteit en 
materiaaleigenschappen zijn onmisbaar geweest bij het analyseren van de mechanische ei-
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Dr. Huddleston-Slater, beste James, bedankt voor je hulp op statistisch gebied en bij de on-
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geweest voor dit proefschrift.
Beste CDL-medewerkers, en in het bijzonder Yvonne, Michel en Arie. Bedankt voor jullie hulp 
en inzet bij de dierstudies.
Beste heren van de instrumentmakerij, bedankt voor het meedenken en het vervaardigen van 
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De stafleden, (oud-)AIOS en assistentes van onze afdeling wil ik bedanken voor de tijd die 
jullie hebben genomen om de verschillende hemostatica te testen op de behandelkamers 
en het anticoagulantiagebruik van de patiënten bij te houden. Daarnaast wil ik iedereen van 
‘beneden’ bedanken voor de prettige werksfeer.
Beste (oud-)medeonderzoekers, bedankt voor de fijne jaren op de 3e verdieping. Het was erg 
prettig om samen de mooie en iets minder mooie momenten van het onderzoek te kunnen 
delen.
Beste Harry, Nienke, Lisa, Angelika en Karin, bedankt voor jullie onmisbare ondersteuning bij 
het onderzoek en de vele gezellige momenten.
Mw. drs. S.H. Visscher, beste Susan, als medebegeleider van mijn scriptie heb ook jij aan de 
basis gestaan van dit onderzoek. Ook na het afronden van de scriptie heb ik veel aan je gehad 
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bij het opzetten van de verschillende studies. Het zou fantastisch zijn als we binnenkort ook 
jouw promotie kunnen vieren.
Mw. drs. Selten, mw. drs. Boerendonk, drs. Meijer en mw. drs. Veele, beste Maaike, Andrea, 
Rolf en Wiesje, als scriptiestudenten hebben jullie actief meegedacht en een belangrijke bij-
drage geleverd aan het onderzoek. Bedankt daarvoor.
Dr. A.C. van Leeuwen, beste Anne, ik kijk met een glimlach terug op onze avonturen in Chili 
en Barcelona. Ik reken op een waardig vervolg in Melbourne.
Dr. N.B. van Bakelen, beste Nico, doordat we tegelijk zijn gestart met ons promotieonderzoek 
en de studie tandheelkunde hebben we de afgelopen jaren veel samen opgetrokken. Bedankt 
voor de vele mooie momenten op de meest uiteenlopende plekken: van Schiermonnikoog tot 
Patagonië en van het Skillslab tot de Toeter. Ik ben blij dat je mijn paranimf wilt zijn.
Dr. R.P.E. Pollard, beste Rodney, ondanks onze sterke verhalen zijn we elkaar ’s nachts vaker 
tegengekomen achter de computer in het UMCG dan in de Rumba. Toch bewaar ik ook aan de 
nachtelijke ontmoetingen in het UMCG goede herinneringen. Ik ben blij dat je mijn paranimf 
wilt zijn.
Mijn jaargenoten bij de studie tandheelkunde, bedankt voor de mooie jaren op de faculteit 
en daarbuiten. 
De oud-collega’s van Mondzorg Midden Drenthe, bedankt voor de prettige samenwerking het 
afgelopen jaar en de mogelijkheid die ik heb gekregen om het afronden van mijn onderzoek 
te combineren met het werk in de praktijk.
Vrienden die me de afgelopen jaren zo vaak van het onderzoek hebben afgehouden. Dennis, 
Thomas, Nathanaël, Feije en Floor, bedankt voor de vele voetbalavondjes en mooie skiva-
kanties. Hein, mooi dat we nooit kunnen voorspellen hoe een avondje Heroes afloopt. Feike 
en René, volgens mij is het weer tijd voor een pokeravondje. Harmen en Irma, geweldig om 
vrienden te hebben waarbij het altijd voelt alsof we elkaar gisteren nog gesproken hebben. 
Het fanatieke pubquizteam, Esther, Mayke, Jardi en Bert, wat hebben we veel nuttige kennis 
opgedaan de afgelopen jaren. Esther, onze wekelijkse spin- en fietstochten gevolgd door nasi 
met zoetzuur waren een perfecte afsluiting van een dag onderzoek. Pim, Ahmed, Sander, Bas, 
Laas, Bouwe, Anouar en Remco, het waren fantastische jaren, dat er nog vele mogen volgen.
Mijn broers, Christiaan en Diederick, als ik met jullie op pad ga is dat een garantie voor mooie 




Mijn ouders, lieve pap en mam, bedankt voor jullie liefdevolle opvoeding en de kansen die ik 
heb gekregen om mezelf te ontplooien. Ik vind het geweldig om te zien met hoeveel liefde 
jullie nu de rol van opa en oma op je nemen. 
Lieve Joline, wat is het fijn om met jou getrouwd te zijn! Bedankt voor je lieve lach, je luiste-
rende oor en je onvoorwaardelijke steun.
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